{"content":"<li class=\"n-box-item date-title\" data-end=\"1561521599\" data-start=\"1561435200\" data-txt=\"Monday, December 23, 2019\">Tuesday, June 25, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3473767\" data-ts=\"1561498600\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473767-micron-technology-leads-after-hour-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Technology leads after hour gainers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a> <font color=\"green\">+10.2%</font>. <a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color=\"green\">+5.9%</font>. <a href='https://seekingalpha.com/symbol/CFMS' title='Conformis, Inc.'>CFMS</a> <font color=\"green\">+4.1%</font>. <a href='https://seekingalpha.com/symbol/SNX' title='SYNNEX Corporation'>SNX</a> <font color=\"green\">+3.3%</font>. <a href='https://seekingalpha.com/symbol/NG' title='NovaGold Resources Inc.'>NG</a> <font color=\"green\">+1.6%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/OCX' title='OncoCyte Corporation'>OCX</a> <font color=\"red\">-12.8%</font>. <a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a> <font color=\"red\">-8.9%</font>. <a href='https://seekingalpha.com/symbol/DTJ' title='DTE Energy Company 2016 Series B 5.375% Sub Deb'>DTJ</a> <font color=\"red\">-3.9%. </font><a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a> <font color=\"red\">-1.3%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473767\" data-linked=\"Micron Technology leads after hour gainers\" data-tweet=\"$MU $INO $CFMS - Micron Technology leads after hour gainers https://seekingalpha.com/news/3473767-micron-technology-leads-after-hour-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473767-micron-technology-leads-after-hour-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473755\" data-ts=\"1561496312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INXN\" target=\"_blank\">INXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473755-interxionminus-2_8-amid-offer-of-4m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InterXion -2.8% amid offer of 4M shares</a></h4><ul>    <li>InterXion (NYSE:<a href='https://seekingalpha.com/symbol/INXN' title='InterXion Holding N.V.'>INXN</a>) is set to <a href=\"https://seekingalpha.com/pr/17555514-interxion-holding-n-v-announces-offering-ordinary-shares\" target=\"_blank\">offer 4M shares</a> in an underwritten offering.</li>    <li>Shares are <font color=\"red\">2.8% lower</font> postmarket.</li>    <li>That comes via Citigroup, Barclays, BofA Merrill Lynch and Guggenheim.</li>    <li>Underwriters will have a 30-day option to buy up to an additional 600,000 shares at the public offering price.</li>    <li>Net proceeds will go to general purposes, including funding land bank development and current and future data center expansion projects.</li>    <li><a href=\"https://seekingalpha.com/filing/4543633\" target=\"_blank\">Shelf registration</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3473755\" data-linked=\"InterXion -2.8% amid offer of 4M shares\" data-tweet=\"$INXN - InterXion -2.8% amid offer of 4M shares https://seekingalpha.com/news/3473755-interxionminus-2_8-amid-offer-of-4m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3473755-interxionminus-2_8-amid-offer-of-4m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473752\" data-ts=\"1561495901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473752-micron-call-nand-wafer-cuts-double-mixed-q4-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron call: NAND wafer cuts double, mixed Q4 guide</a></h4><ul><li>Update with Q4 guidance:</li><li>The Q4 view has revenue within $200M of $4.5B (consensus: $4.56B) and EPS within $0.07 of $0.45 (consensus: $0.70). Gross margin expected within 1.9% of 29% (consensus: 34.8%) and opex within $25M of $785M.</li><li><strong>Original post:</strong> Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>) earnings call includes a further reduction to CY19 NAND wafer starts.</li><li>CY19 DRAM forecast has \"healthy\" Y/Y bit demand growth in H2 with mid-teens growth for the full year, compared to the mid-to-high teens predicted for the industry. The company plans to stick with its 5% idling of wafer starts.</li><li>CY19 NAND bit growth is expected in the mid-30% range compared to the high-30s expected by the industry. Micron targets its bit growth to approach that of the industry. The company is doubling its wafer start cuts from the 5% last quarter to 10%.</li><li>The post will update with more information from the call.</li><li>Micron shares are now <font color=\"green\">up 7.9%</font> while competitor Western Digital (NASDAQ:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) gains <font color=\"green\">3.8%</font> and Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>)<font color=\"green\"> rises 0.8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473752\" data-linked=\"Micron call: NAND wafer cuts double, mixed Q4 guide\" data-tweet=\"$MU $WDC $INTC - Micron call: NAND wafer cuts double, mixed Q4 guide https://seekingalpha.com/news/3473752-micron-call-nand-wafer-cuts-double-mixed-q4-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3473752-micron-call-nand-wafer-cuts-double-mixed-q4-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>110&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473745\" data-ts=\"1561495049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CFMS\" target=\"_blank\">CFMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473745-conformis-secures-33m-capital-raise-shares-up-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Conformis secures $33M capital raise; shares up 5% after hours</a></h4><ul><li>Conformis (NASDAQ:<a href='https://seekingalpha.com/symbol/CFMS' title='Conformis, Inc.'>CFMS</a>) inks <a href=\"https://seekingalpha.com/pr/17555499-conformis-secures-30-million-debt-financing-3-million-equity-financing-innovatus-life\" target=\"_blank\">agreements </a>with Innovatus Capital Partners, LLC and East West Bank for $30M in debt financing and $3M in equity financing from Innovatus.</li><li>The debt will have two parts: a $20M term loan and a $10M credit revolver.</li><li>Innovatus purchased $3M of common stock at $3.87 per share, yesterday's close.</li><li>Proceeds from the debt financing will fund the payoff of a $15M term loan with Oxford Finance LLC.</li><li>Shares are up <font color=\"green\">5%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473745\" data-linked=\"Conformis secures $33M capital raise; shares up 5% after hours\" data-tweet=\"$CFMS - Conformis secures $33M capital raise; shares up 5% after hours https://seekingalpha.com/news/3473745-conformis-secures-33m-capital-raise-shares-up-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3473745-conformis-secures-33m-capital-raise-shares-up-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473739\" data-ts=\"1561494707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBT\" target=\"_blank\">GBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473739-global-blood-down-4-after-hours-on-200m-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Blood down 4% after hours on $200M equity offering</a></h4><ul><li>Global Blood Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics, Inc.'>GBT</a>) slips <font color=\"red\">4%</font> after hours in reaction to its planned <a href=\"https://seekingalpha.com/pr/17555496-global-blood-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">$200M public offering</a> of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473739\" data-linked=\"Global Blood down 4% after hours on $200M equity offering\" data-tweet=\"$GBT - Global Blood down 4% after hours on $200M equity offering https://seekingalpha.com/news/3473739-global-blood-down-4-after-hours-on-200m-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3473739-global-blood-down-4-after-hours-on-200m-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473735\" data-ts=\"1561494401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYES\" target=\"_blank\">EYES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473735-second-sight-up-22-after-hours-on-encouraging-orion-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Second Sight up 22% after hours on encouraging Orion data</a></h4><ul><li>Second Sight Medical Products (NASDAQ:<a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products, Inc.'>EYES</a>) jumps <font color=\"green\">22%</font> after hours in response to <a href=\"https://seekingalpha.com/pr/17555467-researchers-present-latest-positive-results-second-sight-s-orion-visual-cortical-prosthesis\" target=\"_blank\">positive data</a> on six blind patients receiving its Orion Visual Cortical Prosthesis System. The results were presented at the World Society for Stereotactic and Functional Neurosurgery Annual Meeting in New York. </li><li>Four of the six patients have reached the 12-month follow-up point. Three of the four were able to locate a high-contrast target more effectively when the device was turned on compared to off. Three of the four were also able to determine the direction of motion of a high-contrast target significantly better when the device was on versus off.</li><li>On the safety front, two of the six participants experienced an adverse event, including one serious (seizure). There were a total of five non-serious adverse events, none unanticipated.</li><li>Orion converts images captured by a eyeglass-mounted miniature video camera to a series of electrical pulses transmitted wirelessly to electrodes implanted on the brain's visual cortex.</li><li>Development is ongoing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473735\" data-linked=\"Second Sight up 22% after hours on encouraging Orion data\" data-tweet=\"$EYES - Second Sight up 22% after hours on encouraging Orion data https://seekingalpha.com/news/3473735-second-sight-up-22-after-hours-on-encouraging-orion-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3473735-second-sight-up-22-after-hours-on-encouraging-orion-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473730\" data-ts=\"1561494021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WORK\" target=\"_blank\">WORK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473730-baird-gives-slack-bull-start\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird gives Slack a bull start</a></h4><ul><li>Baird starts Slack (NYSE:<a href='https://seekingalpha.com/symbol/WORK' title='Slack Technologies, Inc.'>WORK</a>) with an Outperform rating and a $44 PT, implying a 25% upside.</li><li>WORK shares are <font color=\"green\">up 0.9%</font> after hours to $35.52.</li><li>Slack has an Outperform <a href=\"https://seekingalpha.com/symbol/WORK/ratings/sell-side-ratings\" target=\"_blank\">average Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473730\" data-linked=\"Baird gives Slack a bull start\" data-tweet=\"$WORK - Baird gives Slack a bull start https://seekingalpha.com/news/3473730-baird-gives-slack-bull-start?source=tweet\" data-url=\"https://seekingalpha.com/news/3473730-baird-gives-slack-bull-start\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473726\" data-ts=\"1561493824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNX\" target=\"_blank\">SNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473726-synnex-eps-beats-0_15-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synnex EPS beats by $0.15, beats on revenue</a></h4><ul><li>Synnex (NYSE:<a href='https://seekingalpha.com/symbol/SNX' title='SYNNEX Corporation'>SNX</a>): Q2 Non-GAAP EPS of $2.86 <font color=\"green\">beats by $0.15</font>; GAAP EPS of $2.23 <font color=\"green\">beats by $0.34</font>.</li><li>Revenue of $5.72B (+16.5% Y/Y) <font color=\"green\">beats by $200M</font>.</li><li>Shares <font color=\"green\">+4.6%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17555495-synnex-corporation-reports-second-quarter-fiscal-2019-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3473726\" data-linked=\"Synnex EPS beats by $0.15, beats on revenue\" data-tweet=\"$SNX - Synnex EPS beats by $0.15, beats on revenue https://seekingalpha.com/news/3473726-synnex-eps-beats-0_15-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3473726-synnex-eps-beats-0_15-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473723\" data-ts=\"1561493733\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473723-micronplus-4-on-q3-earnings-strength\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron +4% on Q3 earnings strength</a></h4><ul><li>Update with segment performance info:</li><li>DRAM revenue was down 19% Q/Q and 45% Y/Y. ASPs were down nearly 20% Q/Q, and shipment quantities were relatively flat.</li><li>NAND revenue dropped 18% Q/Q and 25% Y/Y. ASPs were down in the mid-teens percentage range Q/Q, and shipments down mid-single digits.</li><li>More revenue: Compute and Networking, down 13% Q/Q and 48% Y/Y; Mobile, down 27% Q/Q and 33% Y/Y; Storage, down 20% Q/Q and 29% Y/Y; Embedded, down 12% Q/Q and 22% Y/Y.</li><li><strong>Original post:</strong> Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>) <font color=\"green\">+4.2%</font> after <a href=\"https://seekingalpha.com/news/3473712-micron-technology-eps-beats-0_26-beats-revenue\" target=\"_blank\">Q3 beats</a> that topped the highest earnings estimate with a reported $1.05 (consensus: $0.78).</li><li>Adjusted gross margin was 39.3%, down from last year's 60.9% but near the upper end of Micron's guidance.</li><li>Q3 capex totaled $2.21B, leading to FCF of $504M.</li><li>Another capex cut: \"Micron's improved competitive position and strong execution helped us deliver solid results despite a challenging environment. While we are seeing early signs of demand improvement, we plan to reduce our capital expenditures in fiscal 2020 to help improve industry supply-demand balance,\" says CEO Sanjay Mehrotra.</li><li>Earnings call starts at 4:30 PM ET with a webcast <a href=\"https://www.globenewswire.com/Tracker?data=9AM8hiR8ZZomtqG1z1ZpBLZPkSe3dutOW7khR1I7lzpoXDxGHSZQI2eoRIGqc9mjmSmK1tG_F46S64yvhrE9MBQgiFMuwCSr7TY6bwLgO7g=\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17555473-micron-technology-inc-reports-results-third-quarter-fiscal-2019\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473723\" data-linked=\"Micron +4% on Q3 earnings strength\" data-tweet=\"$MU - Micron +4% on Q3 earnings strength https://seekingalpha.com/news/3473723-micronplus-4-on-q3-earnings-strength?source=tweet\" data-url=\"https://seekingalpha.com/news/3473723-micronplus-4-on-q3-earnings-strength\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>122&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473721\" data-ts=\"1561493634\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473721-fedex-points-to-weak-global-trade-drag\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx points to weak global trade as drag</a></h4><ul> <li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) is up slightly after topping <a href=\"https://seekingalpha.com/pr/17555460-fedex-corp-reports-fourth-quarter-full-year-earnings\" target=\"_blank\">FQ4</a> EPS estimates by a comfortable margin on revenue growth of 2.9%.</li> <li>Operating income fell 8% to $1.72B during the quarter on an operating margin rate of 9.6%.</li> <li>Looking ahead, operating income at FedEx Ground and FedEx Freight is expected to increase due to higher revenues. At FedEx Express, macroeconomic weakness and trade uncertainty, continued mix shift to lower-yielding services and a strategic decision to not renew a customer contract are anticipated to negatively impact operating income.</li> <li>\"Our fiscal 2020 performance is being negatively affected by continued weakness in global trade and industrial production, especially at FedEx Express,\" notes FedEx CFO said Alan Graf.</li> <li>Shares of FedEx are <font color=\"green\">up 0.60%</font> AH to $156.05.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3473713-fedex-eps-beats-0_18-misses-revenue\" target=\"_blank\">FedEx EPS beats by $0.18, misses on revenue</a> (June 25)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473721\" data-linked=\"FedEx points to weak global trade as drag\" data-tweet=\"$FDX - FedEx points to weak global trade as drag https://seekingalpha.com/news/3473721-fedex-points-to-weak-global-trade-drag?source=tweet\" data-url=\"https://seekingalpha.com/news/3473721-fedex-points-to-weak-global-trade-drag\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473712\" data-ts=\"1561493226\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473712-micron-technology-eps-beats-0_26-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Technology EPS beats by $0.26, beats on revenue</a></h4><ul><li>Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>): Q3 Non-GAAP EPS of $1.05 <font color=\"green\">beats by $0.26</font>; GAAP EPS of $0.74 <font color=\"green\">beats by $0.15</font>.</li><li>Revenue of $4.79B (-38.6% Y/Y) <font color=\"green\">beats by $90M</font>.</li><li>Shares <font color=\"green\">+2.5%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17555473-micron-technology-inc-reports-results-third-quarter-fiscal-2019\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3473712\" data-linked=\"Micron Technology EPS beats by $0.26, beats on revenue\" data-tweet=\"$MU - Micron Technology EPS beats by $0.26, beats on revenue https://seekingalpha.com/news/3473712-micron-technology-eps-beats-0_26-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3473712-micron-technology-eps-beats-0_26-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>146&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473711\" data-ts=\"1561493189\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRML\" target=\"_blank\">VRML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473711-vermillion-initiates-equity-offering-shares-down-15-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vermillion initiates equity offering; shares down 15% after hours</a></h4><ul><li>Vermillion (NASDAQ:<a href='https://seekingalpha.com/symbol/VRML' title='Vermillion, Inc.'>VRML</a>) launches an unspecified <a href=\"https://seekingalpha.com/pr/17555456-vermillion-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">public offering</a> of common stock. Price, volume and terms have yet to be announced.</li><li>Shares are down <font color=\"red\">15%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473711\" data-linked=\"Vermillion initiates equity offering; shares down 15% after hours\" data-tweet=\"$VRML - Vermillion initiates equity offering; shares down 15% after hours https://seekingalpha.com/news/3473711-vermillion-initiates-equity-offering-shares-down-15-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3473711-vermillion-initiates-equity-offering-shares-down-15-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473710\" data-ts=\"1561493059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ODT\" target=\"_blank\">ODT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473710-odonate-readies-100m-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Odonate readies $100M equity offering</a></h4><ul><li>Odonate Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ODT' title='Odonate Therapeutics, Inc.'>ODT</a>) launches a <a href=\"https://seekingalpha.com/pr/17555439-odonate-therapeutics-announces-public-offering-shares-common-stock\" target=\"_blank\">$100M public offering</a> of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473710\" data-linked=\"Odonate readies $100M equity offering\" data-tweet=\"$ODT - Odonate readies $100M equity offering https://seekingalpha.com/news/3473710-odonate-readies-100m-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3473710-odonate-readies-100m-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473706\" data-ts=\"1561492746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473706-chicken-producers-on-watch-price-fixing-case-gets-serious\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chicken producers on watch as price-fixing case gets more serious</a></h4><ul> <li>Federal prosecutors <a href=\"https://www.bloomberg.com/news/articles/2019-06-25/u-s-probes-claims-of-poultry-price-fixing-at-tyson-pilgrim-s\" target=\"_blank\">disclosed</a> a price-fixing probe of poultry producers Tyson Foods (<a href='https://seekingalpha.com/symbol/TSN' title='Tyson Foods, Inc.'>TSN</a> <font color='red'>-1%</font>), Sanderson Farms (<a href='https://seekingalpha.com/symbol/SAFM' title='Sanderson Farms, Inc.'>SAFM</a> <font color='red'>-2.2%</font>) and Pilgrim's Pride (<a href='https://seekingalpha.com/symbol/PPC' title='Pilgrim&#39;s Pride Corporation'>PPC</a> <font color='red'>-1.3%</font>) as part of their request that depositions in civil litigation be halted for six months to allow the DOJ to proceed.</li> <li>While a cloud has hung over the poultry industry for over a year on allegations that the Georgia Dock Index was fixed, the DOJ involvement raises the stakes quite a bit.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473706\" data-linked=\"Chicken producers on watch as price-fixing case gets more serious\" data-tweet=\"$TSN $SAFM $PPC - Chicken producers on watch as price-fixing case gets more serious https://seekingalpha.com/news/3473706-chicken-producers-on-watch-price-fixing-case-gets-serious?source=tweet\" data-url=\"https://seekingalpha.com/news/3473706-chicken-producers-on-watch-price-fixing-case-gets-serious\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473703\" data-ts=\"1561491703\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCON\" target=\"_blank\">RCON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473703-recon-tech-wins-sales-deal-italys-valvitalia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Recon Tech wins sales deal with Italy&#39;s Valvitalia</a></h4><ul><li>Recon Technology (<a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='green'>+2.8%</font>) says it reached a two-year deal gaining <a href=\"https://seekingalpha.com/pr/17554481-recon-technology-enters-sales-representation-agreement-valvitalia-s-p\" target=\"_blank\">exclusive rights to market</a> Valvitalia's fluid measurement and filtering products to China Petroleum Engineering &amp; Construction Corp.</li><li>Valvitalia is an Italian-based producer of  equipment for measuring, filtering and regulating fluids and gases  serving customers in oil and natural gas, water, petrochemical and utilities markets; it has its products installed in 109 countries.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473703\" data-linked=\"Recon Tech wins sales deal with Italy&#39;s Valvitalia\" data-tweet=\"$RCON - Recon Tech wins sales deal with Italy&#39;s Valvitalia https://seekingalpha.com/news/3473703-recon-tech-wins-sales-deal-italys-valvitalia?source=tweet\" data-url=\"https://seekingalpha.com/news/3473703-recon-tech-wins-sales-deal-italys-valvitalia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473699\" data-ts=\"1561489901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/W\" target=\"_blank\">W</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473699-wayfairminus-5-employees-plan-walkout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wayfair -5% as some employees plan walkout</a></h4><ul> <li>Wayfair (<a href='https://seekingalpha.com/symbol/W' title='Wayfair Inc.'>W</a> <font color='red'>-4.7%</font>) falls on <a href=\"https://www.bloomberg.com/news/articles/2019-06-25/wayfair-faces-worker-outrage-on-sales-to-border-camp-contractors\" target=\"_blank\">reports</a> that some employees are planning to walk out in an organized protest over the online retailer's business dealings with contractors furnishing border detention camps.</li> <li>Twitter account @Wayfairwalkout says 547 employees have signed a letter to Wayfair management over the issue.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473699\" data-linked=\"Wayfair -5% as some employees plan walkout\" data-tweet=\"$W - Wayfair -5% as some employees plan walkout https://seekingalpha.com/news/3473699-wayfairminus-5-employees-plan-walkout?source=tweet\" data-url=\"https://seekingalpha.com/news/3473699-wayfairminus-5-employees-plan-walkout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473695\" data-ts=\"1561489523\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUE\" target=\"_blank\">NUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473695-steel-names-ramp-higher-nucor-hikes-flat-rolled-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steel names ramp higher as Nucor hikes flat rolled prices</a></h4><ul><li>An afternoon surge in steel stocks is attributed to Nucor's (<a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color=\"green\">+1.9%</font>) apparent <a href=\"https://twitter.com/SMUSteel/status/1143570720448045056\" target=\"_blank\">$40/ton price increase</a> on all flat rolled products, effective immediately.</li><li>Also: <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color=\"green\">+4.9%</font>, <a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a> <font color=\"green\">+3.6%</font>, <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corporation'>AKS</a> <font color=\"green\">+2.6%</font>, <a href='https://seekingalpha.com/symbol/SCHN' title='Schnitzer Steel Industries, Inc.'>SCHN</a> <font color=\"green\">+1.7%</font>, <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color=\"green\">+1.6%</font>.</li><li>But NUE's <a href=\"https://www.argusmedia.com/en/news/1928292-nucor-hikes-steel-sheet-prices-40st\" target=\"_blank\">last attempt at raising offers</a>  in January and February by a total of $80/st failed to support prices, as the HRC market ended February at $703/st and has dropped by more than  $180/st since.</li><li>ETF: <a href='https://seekingalpha.com/symbol/SLX' title='VanEck Vectors Steel ETF'>SLX</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3473695\" data-linked=\"Steel names ramp higher as Nucor hikes flat rolled prices\" data-tweet=\"$NUE $X $STLD - Steel names ramp higher as Nucor hikes flat rolled prices https://seekingalpha.com/news/3473695-steel-names-ramp-higher-nucor-hikes-flat-rolled-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3473695-steel-names-ramp-higher-nucor-hikes-flat-rolled-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473694\" data-ts=\"1561489056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473694-mlab-and-shop-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MLAB and SHOP among tech movers</a></h4><ul><li><strong>Gainers: </strong>Vislink Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/VISL' title='Vislink Technologies, Inc.'>VISL</a>) <font color=\"green\">+14%</font>. SilverSun Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SSNT' title='SilverSun Technologies, Inc.'>SSNT</a>) <font color=\"green\">+9%</font>. Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+9%</font>. Mesa Laboratories (NASDAQ:<a href='https://seekingalpha.com/symbol/MLAB' title='Mesa Laboratories, Inc.'>MLAB</a>) <font color=\"green\">+8%</font>. Zedge (NYSEMKT:<a href='https://seekingalpha.com/symbol/ZDGE' title='Zedge, Inc.'>ZDGE</a>) <font color=\"green\">+7%</font>.</li> <li><strong>Losers: </strong>VivoPower International (NASDAQ:<a href='https://seekingalpha.com/symbol/VVPR' title='VivoPower International PLC'>VVPR</a>) <font color=\"red\">-24%</font>. Gravity (NASDAQ:<a href='https://seekingalpha.com/symbol/GRVY' title='Gravity Co., Ltd.'>GRVY</a>) <font color=\"red\">-21%</font>. Neonode (NASDAQ:<a href='https://seekingalpha.com/symbol/NEON' title='Neonode Inc.'>NEON</a>) <font color=\"red\">-11%</font>. Shopify (NYSE:<a href='https://seekingalpha.com/symbol/SHOP' title='Shopify Inc.'>SHOP</a>) <font color=\"red\">-9%</font>. Amtech Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ASYS' title='Amtech Systems, Inc.'>ASYS</a>) <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473694\" data-linked=\"MLAB and SHOP among tech movers\" data-tweet=\"$VISL $SSNT $RIOT - MLAB and SHOP among tech movers https://seekingalpha.com/news/3473694-mlab-and-shop-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473694-mlab-and-shop-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473693\" data-ts=\"1561488478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOS\" target=\"_blank\">MOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473693-mosaic-target-hiked-to-30-cowen-on-higher-earnings-via-brazil-efficiency\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mosaic target hiked to $30 at Cowen on higher earnings via Brazil efficiency</a></h4><ul><li>Mosaic (<a href='https://seekingalpha.com/symbol/MOS' title='The Mosaic Company'>MOS</a> <font color=\"green\">+3%</font>) moves higher after Cowen maintains its Outperform rating and <a href=\"https://www.streetinsider.com/Analyst+Comments/The+Mosaic+Company+%28MOS%29+PT+Jumps+To+%2430+At+Cowen+After+Company+Visit/15641963.html\" target=\"_blank\">raises its stock price target to $30</a> from $26 after the firm returned from a visit to Brazil to meet with management and came away with a far greater appreciation for earnings upside for the Brazil facilities.</li><li>Cowen also raises its FY 2019 estimate for MOS on a rebound in H2 attributed to high corn acreage estimates for spring 2020 and above average application of all nutrients in the fall of 2019, adding that earnings would be even higher if not for the issues in Brazil around tailing dams and the higher cost of production for phosphate chemicals.</li><li>For FY 2020, the firm raises estimates on a combination of better product prices and volumes, a return of Brazilian phosphate facilities to normal operations, and a further increase to Brazil earnings on market gains from both organic growth and further acquisition synergy capture.</li><li>MOS's average <a href=\"https://seekingalpha.com/symbol/MOS/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform and its <a href=\"https://seekingalpha.com/symbol/MOS/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Ranking</a> is Bullish, but its <a href=\"https://seekingalpha.com/symbol/MOS/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473693\" data-linked=\"Mosaic target hiked to $30 at Cowen on higher earnings via Brazil efficiency\" data-tweet=\"$MOS - Mosaic target hiked to $30 at Cowen on higher earnings via Brazil efficiency https://seekingalpha.com/news/3473693-mosaic-target-hiked-to-30-cowen-on-higher-earnings-via-brazil-efficiency?source=tweet\" data-url=\"https://seekingalpha.com/news/3473693-mosaic-target-hiked-to-30-cowen-on-higher-earnings-via-brazil-efficiency\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473692\" data-ts=\"1561488112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473692-poultry-stocks-lower-on-report-of-doj-probe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Poultry stocks lower on report of DOJ probe</a></h4><ul> <li>Shares of Tyson Foods (<a href='https://seekingalpha.com/symbol/TSN' title='Tyson Foods, Inc.'>TSN</a> <font color='red'>-2.2%</font>) and Pilgrim's Pride (<a href='https://seekingalpha.com/symbol/PPC' title='Pilgrim&#39;s Pride Corporation'>PPC</a> <font color='red'>-1.1%</font>) are lower on a Bloomberg headline indicating that the Department of Justice is probing price-fixing allegations in the poultry industry.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3473692\" data-linked=\"Poultry stocks lower on report of DOJ probe\" data-tweet=\"$TSN $PPC - Poultry stocks lower on report of DOJ probe https://seekingalpha.com/news/3473692-poultry-stocks-lower-on-report-of-doj-probe?source=tweet\" data-url=\"https://seekingalpha.com/news/3473692-poultry-stocks-lower-on-report-of-doj-probe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473691\" data-ts=\"1561487994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAR\" target=\"_blank\">PAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473691-par-dips-on-sidotis-sideline-start\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PAR dips on Sidoti&#39;s sideline start</a></h4><ul><li>Sidoti starts PAR Technologies (NYSE:<a href='https://seekingalpha.com/symbol/PAR' title='PAR Technology Corporation'>PAR</a>) with a Neutral rating and $33 PT, representing an 18% upside.</li><li>PAR shares are <font color=\"red\">down 0.5%</font> to $27.93.</li><li>PAR has a Neutral <a href=\"https://seekingalpha.com/symbol/PAR/ratings/quant-ratings\" target=\"_blank\">Quant rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473691\" data-linked=\"PAR dips on Sidoti&#39;s sideline start\" data-tweet=\"$PAR - PAR dips on Sidoti&#39;s sideline start https://seekingalpha.com/news/3473691-par-dips-on-sidotis-sideline-start?source=tweet\" data-url=\"https://seekingalpha.com/news/3473691-par-dips-on-sidotis-sideline-start\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473689\" data-ts=\"1561487747\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHUN\" target=\"_blank\">PHUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473689-phunwareplus-4-on-blockchain-product\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phunware +4% on blockchain product</a></h4><ul><li>Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware, Inc.'>PHUN</a>) <font color=\"green\">gains 4.1%</font> to $3.32 after this morning's <a href=\"https://seekingalpha.com/pr/17554515-phunware-launches-blockchain-enabled-data-exchange-mobile-loyalty-ecosystem\" target=\"_blank\">announced</a> blockchain-enabled data exchange and mobile loyalty ecosystem for customers, who will be paid in PhunCoin for participating.</li><li>PHUN has created more than 2.5B Phunware IDs representing connected mobile devices. The company expects to extend the offerings to new enterprise customers in H2.</li><li>Phunware shares rose as much as 58% in pre-market trading today before paring those gains.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473689\" data-linked=\"Phunware +4% on blockchain product\" data-tweet=\"$PHUN - Phunware +4% on blockchain product https://seekingalpha.com/news/3473689-phunwareplus-4-on-blockchain-product?source=tweet\" data-url=\"https://seekingalpha.com/news/3473689-phunwareplus-4-on-blockchain-product\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473682\" data-ts=\"1561485615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473682-mcdermott-and-key-energy-services-among-energy-materials-gainers-basic-energy-services-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McDermott and Key Energy Services among Energy/Materials gainers; Basic Energy Services and Epsilon Energy among losers</a></h4><ul><li><b>Gainers: </b>McDermott (NYSE:<a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a>) <font color=\"green\">+6%</font>. Key Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a>) <font color=\"green\">+6%</font>. Quintana Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/QES' title='Quintana Energy Services Inc.'>QES</a>) <font color=\"green\">+6%</font>. Laredo Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/LPI' title='Laredo Petroleum, Inc.'>LPI</a>) <font color=\"green\">+6%</font>. Frank's International (NYSE:<a href='https://seekingalpha.com/symbol/FI' title='Frank&#39;s International N.V.'>FI</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Basic Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/BAS' title='Basic Energy Services, Inc.'>BAS</a>) <font color=\"red\">-12%</font>. Epsilon Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/EPSN' title='Epsilon Energy Ltd.'>EPSN</a>) <font color=\"red\">-9%</font>. Barnwell Industries (NYSEMKT:<a href='https://seekingalpha.com/symbol/BRN' title='Barnwell Industries, Inc.'>BRN</a>) <font color=\"red\">-7%</font>. Southwestern Energy (NYSE:<a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Company'>SWN</a>) <font color=\"red\">-6%</font>. MAG Silver (NYSEMKT:<a href='https://seekingalpha.com/symbol/MAG' title='MAG Silver Corp.'>MAG</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473682\" data-linked=\"McDermott and Key Energy Services among Energy/Materials gainers; Basic Energy Services and Epsilon Energy among losers\" data-tweet=\"$MDR $KEG $QES - McDermott and Key Energy Services among Energy/Materials gainers; Basic Energy Services and Epsilon Energy among losers https://seekingalpha.com/news/3473682-mcdermott-and-key-energy-services-among-energy-materials-gainers-basic-energy-services-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3473682-mcdermott-and-key-energy-services-among-energy-materials-gainers-basic-energy-services-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473673\" data-ts=\"1561483863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPTN\" target=\"_blank\">SPTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473673-spartannashplus-5-after-loop-pitches-bull-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SpartanNash +5% after Loop pitches bull case</a></h4><ul> <li>SpartanNash (<a href='https://seekingalpha.com/symbol/SPTN' title='SpartanNash Company'>SPTN</a> <font color='green'>+5.2%</font>) gains after Loop Capital Markets initiates <a href=\"https://seekingalpha.com/symbol/SPTN/ratings/sell-side-ratings\" target=\"_blank\">coverage</a> on the food distributor with a Buy rating.</li> <li>Loop's bullish view on SpartanNash stands above the sell-side consensus rating of Hold.</li> <li>Loop sets a price target of $15 on SpartanNash.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473673\" data-linked=\"SpartanNash +5% after Loop pitches bull case\" data-tweet=\"$SPTN - SpartanNash +5% after Loop pitches bull case https://seekingalpha.com/news/3473673-spartannashplus-5-after-loop-pitches-bull-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3473673-spartannashplus-5-after-loop-pitches-bull-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473664\" data-ts=\"1561482039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473664-hydrogenics-leads-industrial-gainers-lennar-and-cemtrex-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hydrogenics leads industrial gainers; Lennar and Cemtrex among losers</a></h4><ul><li><b>Gainers: </b>Hydrogenics (NASDAQ:<a href='https://seekingalpha.com/symbol/HYGS' title='Hydrogenics Corporation'>HYGS</a>) <font color=\"green\">+7%</font>. Art's-Way Manufacturing (NASDAQ:<a href='https://seekingalpha.com/symbol/ARTW' title='Art&#39;s-Way Manufacturing Co., Inc.'>ARTW</a>) <font color=\"green\">+6%</font>. Triumph Group (NYSE:<a href='https://seekingalpha.com/symbol/TGI' title='Triumph Group, Inc.'>TGI</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Cemtrex (NASDAQ:<a href='https://seekingalpha.com/symbol/CETX' title='Cemtrex, Inc.'>CETX</a>) <font color=\"red\">-26%</font>. Forterra (NASDAQ:<a href='https://seekingalpha.com/symbol/FRTA' title='Forterra, Inc.'>FRTA</a>) <font color=\"red\">-11%</font>. Euro Tech Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CLWT' title='Euro Tech Holdings Company Limited'>CLWT</a>) <font color=\"red\">-9%</font>. Coda Octopus Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CODA' title='Coda Octopus Group, Inc.'>CODA</a>) <font color=\"red\">-7%</font>. Lennar (NYSE:<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473664\" data-linked=\"Hydrogenics leads industrial gainers; Lennar and Cemtrex among losers\" data-tweet=\"$HYGS $ARTW $TGI - Hydrogenics leads industrial gainers; Lennar and Cemtrex among losers https://seekingalpha.com/news/3473664-hydrogenics-leads-industrial-gainers-lennar-and-cemtrex-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473664-hydrogenics-leads-industrial-gainers-lennar-and-cemtrex-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473663\" data-ts=\"1561481956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLOG\" target=\"_blank\">GLOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473663-gaslog-upgraded-gaslog-partners-cut-stifel-after-idr-exchange\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GasLog upgraded, GasLog Partners cut at Stifel after IDR exchange</a></h4><ul><li>GasLog (<a href='https://seekingalpha.com/symbol/GLOG' title='GasLog Ltd.'>GLOG</a> <font color=\"green\">+5.6%</font>) jumps after Stifel <a href=\"https://thefly.com/thestreet/realmoney/index.php/GLOG;GLOPid2925908/GLOG;GLOP-GasLog-upgraded-to-Buy-from-Hold-at-Stifel\" target=\"_blank\">upgrades shares to Buy</a> from Hold with an $18 price target, up from $17, as analyst Benjamin Nolan cites valuation and his expectation for strong liquefied natural gas charter rates in this year's H2.</li><li>Nolan also cites \"favorable terms\" for the <a href=\"https://seekingalpha.com/pr/17552717-gaslog-ltd-gaslog-partners-lp-announce-agreement-eliminate-incentive-distribution-rights\" target=\"_blank\">buyout of incentive distribution rights</a> from the GasLog Partners (<a href='https://seekingalpha.com/symbol/GLOP' title='GasLog Partners LP'>GLOP</a> <font color=\"red\">-1.7%</font>) partnership; in exchange for the IDRs, GLOG will receive more than 2.53M common units and 2.49M newly issued Class B units.</li><li>At the same time, Nolan <a href=\"https://thefly.com/thestreet/realmoney/index.php/GLOP;GLOGid2925907/GLOP;GLOG-GasLog-Partners-downgraded-to-Hold-from-Buy-at-Stifel\" target=\"_blank\">downgrades</a> GLOP to Hold from Buy with an unchanged $22 price target, citing the agreement to eliminate the IDRs in exchange for limited partner units at a \"higher than necessary\" price.</li><li>GLOG's average <a href=\"https://seekingalpha.com/symbol/GLOG/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Buy and its <a href=\"https://seekingalpha.com/symbol/GLOG/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> is Very Bullish, but its <a href=\"https://seekingalpha.com/symbol/GLOG/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Very Bearish.</li><li>GLOP's average <a href=\"https://seekingalpha.com/symbol/GLOP/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform, while both its <a href=\"https://seekingalpha.com/symbol/GLOP/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> and <a href=\"https://seekingalpha.com/symbol/GLOP/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473663\" data-linked=\"GasLog upgraded, GasLog Partners cut at Stifel after IDR exchange\" data-tweet=\"$GLOG $GLOP - GasLog upgraded, GasLog Partners cut at Stifel after IDR exchange https://seekingalpha.com/news/3473663-gaslog-upgraded-gaslog-partners-cut-stifel-after-idr-exchange?source=tweet\" data-url=\"https://seekingalpha.com/news/3473663-gaslog-upgraded-gaslog-partners-cut-stifel-after-idr-exchange\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473662\" data-ts=\"1561481644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473662-mmtec-and-scully-royalty-among-financial-gainers-brighthouse-financial-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mmtec and Scully Royalty among financial gainers, Brighthouse Financial leads losers</a></h4><ul><li><b>Gainers:</b> Mmtec (NASDAQ:<a href='https://seekingalpha.com/symbol/MTC' title='Mmtec, Inc.'>MTC</a>) <font color=\"green\">+8%</font>. MoneyGram International (NASDAQ:<a href='https://seekingalpha.com/symbol/MGI' title='MoneyGram International, Inc.'>MGI</a>) <font color=\"green\">+7%</font>. Scully Royalty (NYSE:<a href='https://seekingalpha.com/symbol/SRL' title='Scully Royalty Ltd.'>SRL</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> Brighthouse Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/BHF' title='Brighthouse Financial, Inc.'>BHF</a>) <font color=\"red\">-14%</font>. Golden Bull (NASDAQ:<a href='https://seekingalpha.com/symbol/DNJR' title='Golden Bull Limited'>DNJR</a>) <font color=\"red\">-10%</font>. Yintech Investment Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings Limited'>YIN</a>) <font color=\"red\">-6%</font>. Arlington Asset Investment (NYSE:<a href='https://seekingalpha.com/symbol/AI' title='Arlington Asset Investment Corp.'>AI</a>) <font color=\"red\">-6%</font>. LexinFintech Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LX' title='LexinFintech Holdings Ltd.'>LX</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473662\" data-linked=\"Mmtec and Scully Royalty among financial gainers, Brighthouse Financial leads losers\" data-tweet=\"$MTC $MGI $SRL - Mmtec and Scully Royalty among financial gainers, Brighthouse Financial leads losers https://seekingalpha.com/news/3473662-mmtec-and-scully-royalty-among-financial-gainers-brighthouse-financial-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473662-mmtec-and-scully-royalty-among-financial-gainers-brighthouse-financial-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473659\" data-ts=\"1561481303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEN\" target=\"_blank\">LEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473659-lennarminus-6_3-average-selling-prices-slip-tariffs-rise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lennar -6.3% as average selling prices slip, tariffs rise</a></h4><ul><li>Lennar (NYSE:<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a>) <font color=\"red\">falls 6.3%</font>, wiping out an earlier gain, as executives warned of lower average sales prices on the company's Q2 earnings call.</li><li>\"As many new entry-level communities come online,\" the average selling price will continue to slip, they said, particularly in Texas.</li><li>Tariffs on materials pose another headwind: \"On average, the impact to us is about $500 per home.\"</li><li>Higher land and labor costs also add to pressures.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3473500-lennar-plus-5_2-percent-q2-results-beats-sees-fatter-margins\" target=\"_blank\">Lennar +5.2% as Q2 results beats; sees fatter margins</a> (June 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3473659\" data-linked=\"Lennar -6.3% as average selling prices slip, tariffs rise\" data-tweet=\"$LEN - Lennar -6.3% as average selling prices slip, tariffs rise https://seekingalpha.com/news/3473659-lennarminus-6_3-average-selling-prices-slip-tariffs-rise?source=tweet\" data-url=\"https://seekingalpha.com/news/3473659-lennarminus-6_3-average-selling-prices-slip-tariffs-rise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473657\" data-ts=\"1561481132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PZG\" target=\"_blank\">PZG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473657-paramount-gold-to-launch-grassy-mountain-feasibility-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paramount Gold to launch Grassy Mountain feasibility study</a></h4><ul><li>Paramount Gold Nevada (<a href='https://seekingalpha.com/symbol/PZG' title='Paramount Gold Nevada Corp.'>PZG</a> <font color='green'>+4.1%</font>) says it entered into an agreement  with Ausenco Engineering Canada to <a href=\"https://seekingalpha.com/pr/17554135-paramount-gold-enters-agreement-ausenco-complete-bankable-feasibility-study-grassy-mountain\" target=\"_blank\">complete a feasibility study</a> for its proposed Grassy Mountain gold mine in Oregon.</li><li>Ausenco will receive 100% of its fees in PZG restricted common stock, resulting in the issuance of more than 1.1M shares to the engineering firm.</li><li>PZG says it expects to have all Grassy Mountain permits in place in 2020 and is preparing to initiate construction immediately following receiving all permits.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473657\" data-linked=\"Paramount Gold to launch Grassy Mountain feasibility study\" data-tweet=\"$PZG $AUEOF - Paramount Gold to launch Grassy Mountain feasibility study https://seekingalpha.com/news/3473657-paramount-gold-to-launch-grassy-mountain-feasibility-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3473657-paramount-gold-to-launch-grassy-mountain-feasibility-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473655\" data-ts=\"1561480422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473655-healthcare-and-tech-dominate-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare and Tech dominate midday movers</a></h4><ul><li><strong>Gainers: </strong>Pyxus International (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"green\">+28%</font>. Allergan (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) <font color=\"green\">+26%</font>. ENDRA Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NDRA' title='ENDRA Life Sciences Inc.'>NDRA</a>) <font color=\"green\">+23%</font>. Pier 1 Imports (NYSE:<a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports, Inc.'>PIR</a>) <font color=\"green\">+18%</font>. Rafael Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/RFL' title='Rafael Holdings, Inc.'>RFL</a>) <font color=\"green\">+16%</font>. Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+15%</font>. Vislink Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/VISL' title='Vislink Technologies, Inc.'>VISL</a>) <font color=\"green\">+15%</font>. Odyssey Marine Exploration (NASDAQ:<a href='https://seekingalpha.com/symbol/OMEX' title='Odyssey Marine Exploration, Inc.'>OMEX</a>) <font color=\"green\">+13%</font>. Infrastructure and Energy Alternatives (NASDAQ:<a href='https://seekingalpha.com/symbol/IEA' title='Infrastructure and Energy Alternatives, Inc.'>IEA</a>) <font color=\"green\">+13%</font>. Xencor (NASDAQ:<a href='https://seekingalpha.com/symbol/XNCR' title='Xencor, Inc.'>XNCR</a>) <font color=\"green\">+13%</font>.</li> <li><strong>Losers: </strong>Acer Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACER' title='Acer Therapeutics Inc.'>ACER</a>) <font color=\"red\">-77%</font>. Immunic (NASDAQ:<a href='https://seekingalpha.com/symbol/IMUX' title='Immunic, Inc.'>IMUX</a>) <font color=\"red\">-27%</font>. Cemtrex (NASDAQ:<a href='https://seekingalpha.com/symbol/CETX' title='Cemtrex, Inc.'>CETX</a>) <font color=\"red\">-24%</font>. Gamida Cell (NASDAQ:<a href='https://seekingalpha.com/symbol/GMDA' title='Gamida Cell Ltd.'>GMDA</a>) <font color=\"red\">-23%</font>. VivoPower International (NASDAQ:<a href='https://seekingalpha.com/symbol/VVPR' title='VivoPower International PLC'>VVPR</a>) <font color=\"red\">-23%</font>. Aldeyra Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>) <font color=\"red\">-18%</font>. Gravity (NASDAQ:<a href='https://seekingalpha.com/symbol/GRVY' title='Gravity Co., Ltd.'>GRVY</a>) <font color=\"red\">-17%</font>. AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) <font color=\"red\">-15%</font>. Brighthouse Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/BHF' title='Brighthouse Financial, Inc.'>BHF</a>) <font color=\"red\">-14%</font>. Basic Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/BAS' title='Basic Energy Services, Inc.'>BAS</a>) <font color=\"red\">-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473655\" data-linked=\"Healthcare and Tech dominate midday movers\" data-tweet=\"$PYX $AGN $NDRA - Healthcare and Tech dominate midday movers https://seekingalpha.com/news/3473655-healthcare-and-tech-dominate-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473655-healthcare-and-tech-dominate-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473650\" data-ts=\"1561479343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDRA\" target=\"_blank\">NDRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473650-endra-up-19-ahead-of-taeus-showcase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endra up 19% ahead of TAEUS showcase</a></h4><ul><li>Thinly traded nano cap ENDRA Life Sciences (<a href='https://seekingalpha.com/symbol/NDRA' title='ENDRA Life Sciences Inc.'>NDRA</a> <font color=\"green\">+19.3%</font>) is up more than triple normal volume, albeit on turnover of only 574K shares, ahead of this week's International Conference on Fatty Liver in Berlin. The company plans to <a href=\"https://seekingalpha.com/pr/17552992-endra-life-sciences-showcase-taeus-tm-liver-application-2nd-international-conference-fatty\" target=\"_blank\">showcase </a>its next-generation Thermo-Acoustic Enhanced UltraSound &#40;TAEUS&#41; platform that it says enables clinicians to visualize tissue composition, function and temperature in ways that were previously possible only with CT and MRI.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473650\" data-linked=\"Endra up 19% ahead of TAEUS showcase\" data-tweet=\"$NDRA - Endra up 19% ahead of TAEUS showcase https://seekingalpha.com/news/3473650-endra-up-19-ahead-of-taeus-showcase?source=tweet\" data-url=\"https://seekingalpha.com/news/3473650-endra-up-19-ahead-of-taeus-showcase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473648\" data-ts=\"1561478832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473648-pyxus-international-and-neenah-in-consumer-gainers-dean-foods-and-cryoport-in-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pyxus International and Neenah in consumer gainers; Dean Foods and Cryoport in losers</a></h4><ul><li><b>Gainers: </b>Pyxus International (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"green\">+26%</font>. Neenah (NYSE:<a href='https://seekingalpha.com/symbol/NP' title='Neenah, Inc.'>NP</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Cryoport (NASDAQ:<a href='https://seekingalpha.com/symbol/CYRX' title='Cryoport, Inc.'>CYRX</a>) <font color=\"red\">-6%</font>. Dean Foods (NYSE:<a href='https://seekingalpha.com/symbol/DF' title='Dean Foods Company'>DF</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473648\" data-linked=\"Pyxus International and Neenah in consumer gainers; Dean Foods and Cryoport in losers\" data-tweet=\"$PYX $NP $CYRX - Pyxus International and Neenah in consumer gainers; Dean Foods and Cryoport in losers https://seekingalpha.com/news/3473648-pyxus-international-and-neenah-in-consumer-gainers-dean-foods-and-cryoport-in-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473648-pyxus-international-and-neenah-in-consumer-gainers-dean-foods-and-cryoport-in-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473645\" data-ts=\"1561478371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473645-competing-pg-and-e-bankruptcy-reorg-plan-worth-up-to-30b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Competing PG&amp;E bankruptcy reorg plan worth up to $30B</a></h4><ul><li>A committee of PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color=\"green\">+2%</font>) bondholders has filed a <a href=\"https://www.reuters.com/article/us-pg-e-us-bankruptcy/pge-bondholders-propose-competing-bankruptcy-plan-idUSKCN1TQ21D\" target=\"_blank\">competing reorganization plan</a> to the San Francisco bankruptcy court that would inject as much as $30B, primarily equity, to help the utility emerge  from Chapter 11 and address liability from wildfires.</li><li>The committee of senior unsecured noteholders also seeks to terminate PG&amp;E's exclusive period to file and confirm its own bankruptcy plan, saying \"the need to exit bankruptcy expeditiously is paramount\" and PG&amp;E has been too slow to file a plan.</li><li>The plan also would provide a \"substantial\" capital investment to fund improvements to PG&amp;E's electric infrastructure to ensure reliable power service and meet California's renewable energy goals.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473645\" data-linked=\"Competing PG&amp;E bankruptcy reorg plan worth up to $30B\" data-tweet=\"$PCG - Competing PG&amp;E bankruptcy reorg plan worth up to $30B https://seekingalpha.com/news/3473645-competing-pg-and-e-bankruptcy-reorg-plan-worth-up-to-30b?source=tweet\" data-url=\"https://seekingalpha.com/news/3473645-competing-pg-and-e-bankruptcy-reorg-plan-worth-up-to-30b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473634\" data-ts=\"1561478141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAK\" target=\"_blank\">TAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473634-pharma-players-in-green-on-abbvie-allergan-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pharma players in green on AbbVie/Allergan deal</a></h4><ul><li>Members of Big Biopharma, with the notable exception of AbbVie, are all enjoying a spike in buying after its <a href=\"https://seekingalpha.com/news/3473483-abbvie-poised-take-allergan-60b\" target=\"_blank\">$63B bid</a> for Allergan, stoking hopes that big healthcare mergers are back in play.</li><li>Selected tickers: Takeda (<a href='https://seekingalpha.com/symbol/TAK' title='Takeda Pharmaceutical Company Limited'>TAK</a> <font color=\"green\">+1.3%</font>), Bausch Health Companies (<a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a> <font color=\"green\">+4.2%</font>), Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding AG'>OTCQX:RHHBY</a> <font color=\"green\">+0.2%</font>), AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a> <font color=\"green\">+0.2%</font>), Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=\"green\">+1%</font>), GlaxoSmithKline (<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline plc'>GSK</a> <font color=\"green\">+0.6%</font>), Johnson &amp; Johnson (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color=\"green\">+0.6%</font>), Eli Lilly (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color=\"green\">+0.7%</font>), Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a>), Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color=\"green\">+0.7%</font>), Pfizer (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color=\"green\">+0.6%</font>), Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color=\"green\">+6.4%</font>), Amgen (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color=\"green\">+0.9%</font>), Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"green\">+3.1%</font>), Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color=\"green\">+1%</font>), Vertex Pharmaceuticals (<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color=\"green\">+0.3%</font>)</li><li>ETFs: (<a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a> <font color=\"green\">+3.4%</font>), (<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color=\"green\">+0.9%</font>), (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color=\"green\">+0.9%</font>), (<a href='https://seekingalpha.com/symbol/PJP' title='Invesco Dynamic Pharmaceuticals Portfolio ETF'>PJP</a> <font color=\"green\">+1.2%</font>), (<a href='https://seekingalpha.com/symbol/IHE' title='iShares U.S. Pharmaceuticals ETF'>IHE</a> <font color=\"green\">+2.3%</font>), (<a href='https://seekingalpha.com/symbol/PPH' title='VanEck Vectors Pharmaceutical ETF'>PPH</a> <font color=\"green\">+0.6%</font>), (<a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a> <font color=\"green\">+0.1%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3473634\" data-linked=\"Pharma players in green on AbbVie/Allergan deal\" data-tweet=\"$TAK $BHC $RHHBY - Pharma players in green on AbbVie/Allergan deal https://seekingalpha.com/news/3473634-pharma-players-in-green-on-abbvie-allergan-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3473634-pharma-players-in-green-on-abbvie-allergan-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473641\" data-ts=\"1561477763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473641-facebook-launches-issue-ad-transparency-tools-worldwide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook launches issue ad transparency tools worldwide</a></h4><ul>   <li>Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color=\"red\">-1.7%</font>) is giving a <a href=\"https://newsroom.fb.com/news/2019/06/offering-greater-transparency/\" target=\"_blank\">global rollout</a> to its transparency tools for advertisers, looking to add clarity on ads placed about social issues, elections and politics.</li>    <li>That includes bringing previously built advertiser authentication to new countries: Facebook will confirm advertiser IDs and allow them to disclose who's responsible for a given ad. That and other information will be placed in Facebook's Ad Library for seven years.</li>    <li>It's also requiring more authorizations and disclaimers, noting \"Elections are happening all over the world and some happen with very little notice.\"</li>    <li>Along with the rollout, it's expanding access to the Ad Library API globally, \"so regulators, journalists, watchdog groups and other people can analyze ads about social issues, elections or politics and help hold advertisers and Facebook accountable.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473641\" data-linked=\"Facebook launches issue ad transparency tools worldwide\" data-tweet=\"$FB - Facebook launches issue ad transparency tools worldwide https://seekingalpha.com/news/3473641-facebook-launches-issue-ad-transparency-tools-worldwide?source=tweet\" data-url=\"https://seekingalpha.com/news/3473641-facebook-launches-issue-ad-transparency-tools-worldwide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473628\" data-ts=\"1561475815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VBIV\" target=\"_blank\">VBIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473628-vbi-vaccines-down-12-ahead-of-corporate-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VBI Vaccines down 12% ahead of corporate presentation</a></h4><ul><li>VBI Vaccines (<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines Inc.'>VBIV</a> <font color=\"red\">-12.4%</font>) is down on more than a 5x surge in volume ahead of a <a href=\"https://seekingalpha.com/pr/17550551-vbi-vaccines-present-bmo-capital-markets-2019-prescriptions-success-healthcare-conference\" target=\"_blank\">corporate presentation</a> today at the BMO Capital Markets Healthcare Conference by President &amp; CEO Jeff Baxter. He is scheduled to take the podium at 11:20 am ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473628\" data-linked=\"VBI Vaccines down 12% ahead of corporate presentation\" data-tweet=\"$VBIV - VBI Vaccines down 12% ahead of corporate presentation https://seekingalpha.com/news/3473628-vbi-vaccines-down-12-ahead-of-corporate-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3473628-vbi-vaccines-down-12-ahead-of-corporate-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473624\" data-ts=\"1561475404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGNX\" target=\"_blank\">PGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473624-progenics-up-6-on-pyl-data-in-prostate-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progenics up 6% on PyL data in prostate cancer</a></h4><ul><li>Progenics Pharmaceuticals (<a href='https://seekingalpha.com/symbol/PGNX' title='Progenics Pharmaceuticals, Inc.'>PGNX</a> <font color=\"green\">+5.9%</font>) is up on below-average volume on the heels of results from a Phase 2/3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02981368?lead=progenics&amp;phase=2&amp;rank=2\" target=\"_blank\">OSPREY</a>, evaluating PSMA-targeted PET imaging agent PyL in men with high-risk metastatic prostate cancer and an investigator-sponsored study assessing PyL in men with biochemically recurrent prostate cancer. The <a href=\"https://seekingalpha.com/pr/17554499-data-presented-society-nuclear-medicine-molecular-imaging-snmmi-2019-annual-meeting\" target=\"_blank\">data were presented</a> at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Anaheim, CA.</li><li>The company says the collective data show PyL's ability to detect locally advanced, biochemically recurrent and metastatic prostate cancer.</li><li>A Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03739684?lead=progenics&amp;phase=2&amp;rank=1\" target=\"_blank\">CONDOR</a>, is in process with an estimated completion date of January 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473624\" data-linked=\"Progenics up 6% on PyL data in prostate cancer\" data-tweet=\"$PGNX - Progenics up 6% on PyL data in prostate cancer https://seekingalpha.com/news/3473624-progenics-up-6-on-pyl-data-in-prostate-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3473624-progenics-up-6-on-pyl-data-in-prostate-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473618\" data-ts=\"1561474927\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473618-allergan-leads-healthcare-gainers-acer-therapeutics-tops-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan leads healthcare gainers; Acer Therapeutics tops the losers</a></h4><ul><li><b>Gainers: </b>Allergan (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) <font color=\"green\">+27%</font>. ENDRA Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NDRA' title='ENDRA Life Sciences Inc.'>NDRA</a>) <font color=\"green\">+13%</font>. Xencor (NASDAQ:<a href='https://seekingalpha.com/symbol/XNCR' title='Xencor, Inc.'>XNCR</a>) <font color=\"green\">+13%</font>. ARCA biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ABIO' title='ARCA biopharma, Inc.'>ABIO</a>) <font color=\"green\">+11%</font>. Krystal Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/KRYS' title='Krystal Biotech, Inc.'>KRYS</a>) <font color=\"green\">+10%</font>.</li><li><b>Losers: </b>Acer Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACER' title='Acer Therapeutics Inc.'>ACER</a>) <font color=\"red\">-77%</font>. Immunic (NASDAQ:<a href='https://seekingalpha.com/symbol/IMUX' title='Immunic, Inc.'>IMUX</a>) <font color=\"red\">-25%</font>. Gamida Cell (NASDAQ:<a href='https://seekingalpha.com/symbol/GMDA' title='Gamida Cell Ltd.'>GMDA</a>) <font color=\"red\">-23%</font>. Aldeyra Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>) <font color=\"red\">-21%</font>. VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines Inc.'>VBIV</a>) <font color=\"red\">-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473618\" data-linked=\"Allergan leads healthcare gainers; Acer Therapeutics tops the losers\" data-tweet=\"$AGN $NDRA $XNCR - Allergan leads healthcare gainers; Acer Therapeutics tops the losers https://seekingalpha.com/news/3473618-allergan-leads-healthcare-gainers-acer-therapeutics-tops-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473618-allergan-leads-healthcare-gainers-acer-therapeutics-tops-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473615\" data-ts=\"1561474321\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GMDA\" target=\"_blank\">GMDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473615-gamida-down-23-on-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gamida down 23% on equity offering</a></h4><ul><li>Thinly traded micro cap Gamida Cell Ltd. (<a href='https://seekingalpha.com/symbol/GMDA' title='Gamida Cell Ltd.'>GMDA</a> <font color=\"red\">-22.9%</font>) is down on more than triple normal volume, albeit on turnover of only 60K shares, in response to its <a href=\"https://seekingalpha.com/pr/17553682-gamida-cell-announces-launch-proposed-public-offering-ordinary-shares\" target=\"_blank\">$30M public offering</a> of ordinary shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473615\" data-linked=\"Gamida down 23% on equity offering\" data-tweet=\"$GMDA - Gamida down 23% on equity offering https://seekingalpha.com/news/3473615-gamida-down-23-on-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3473615-gamida-down-23-on-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473616\" data-ts=\"1561474313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473616-amazon-launches-roku-tv-competitor-rokuminus-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon launches Roku TV competitor; ROKU -3%</a></h4><ul><li>Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku, Inc.'>ROKU</a>) shares <font color=\"red\">drop 3%</font> after <a href=\"https://arstechnica.com/gadgets/2019/06/amazon-takes-on-tcls-roku-tv-with-low-cost-hdr-fire-tv-television/\" target=\"_blank\"><em>Ars Technica</em></a> highlights Amazon's (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='red'>-1.4%</font>) new smart televisions.</li><li>Amazon's Toshiba 4K UHD Smart TV HDR has an LCD panel with a contrast ratio of 4,000:1 and HDR in the Dolby Vision standard, a 4K refresh rate, and a 60Hz refresh rate.</li><li>Pricing: 43-inch model for $329.99, 50-inch for $379.99, and 55-inch for $449.99.</li><li>Availability: The largest model is available now, and the others will launch on June 30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473616\" data-linked=\"Amazon launches Roku TV competitor; ROKU -3%\" data-tweet=\"$ROKU $AMZN - Amazon launches Roku TV competitor; ROKU -3% https://seekingalpha.com/news/3473616-amazon-launches-roku-tv-competitor-rokuminus-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3473616-amazon-launches-roku-tv-competitor-rokuminus-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473608\" data-ts=\"1561473733\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CZR\" target=\"_blank\">CZR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473608-morgan-stanley-eyes-potential-caesars-scenarios\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley eyes potential Caesars scenarios</a></h4><ul> <li>Caesars Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment Corporation'>CZR</a>) is <font color=\"green\">up 2.23%</font> as shares move closer to the cash/stock Eldorado deal price of $12.50.</li> <li>The deal process could see shares swing up or down, according to Morgan Stanley.</li> <li>\"We see potential bull case where the mkt values CZR at Friday's multiples inclusive of &gt;$500m of synergies, implying $15. However, we see a (less likely) bear case the deal falls apart and the stock trades to $9,\" advises Morgan Stanley gaming analyst Thomas Allen.</li><li>MS plays it down the middle roughly with a price target set at $12.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473608\" data-linked=\"Morgan Stanley eyes potential Caesars scenarios\" data-tweet=\"$CZR - Morgan Stanley eyes potential Caesars scenarios https://seekingalpha.com/news/3473608-morgan-stanley-eyes-potential-caesars-scenarios?source=tweet\" data-url=\"https://seekingalpha.com/news/3473608-morgan-stanley-eyes-potential-caesars-scenarios\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473607\" data-ts=\"1561473560\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473607-baupost-on-short-end-of-allergan-deal-100m-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baupost on short end of Allergan deal with $100M loss</a></h4><ul><li>Seth Klarman's Baupost Group is poised for almost a $100M loss on its Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color=\"green\">+27%</font>) stake based on AbbVie's (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color=\"red\">-14.4%</font>) $188.24 per share bid. Baupost owns 4.8M common shares at a cost basis of $208.61 according to <a href=\"https://www.bloomberg.com/news/articles/2019-06-25/baupost-s-klarman-loses-in-allergan-deal-while-tepper-gets-a-win?utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;utm_content=business&amp;utm_medium=social&amp;cmpid=socialflow-twitter-business\" target=\"_blank\">Bloomberg data</a>. Mr. Klarman initiated his position in Q1 2016 when AGN was close to a merger with Pfizer (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color=\"green\">+0.4%</font>).</li><li>Activist investor Appaloosa, owner of ~3.1M AGN shares at a cost basis of $160.61, is set for a tidy profit of ~$86M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473607\" data-linked=\"Baupost on short end of Allergan deal with $100M loss\" data-tweet=\"$AGN $ABBV $PFE - Baupost on short end of Allergan deal with $100M loss https://seekingalpha.com/news/3473607-baupost-on-short-end-of-allergan-deal-100m-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3473607-baupost-on-short-end-of-allergan-deal-100m-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>107&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473602\" data-ts=\"1561472614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473602-3d-printers-rise-on-260m-startup-funding\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3D printers rise on $260M startup funding</a></h4><ul><li>Private digital manufacturing and 3D printing platform company Carbon <a href=\"https://venturebeat.com/2019/06/25/3d-printing-platform-carbon-raises-260-million-at-2-4-billion-valuation/\" target=\"_blank\">announces </a>a $260M funding round led by Madrone Capital Partners and Baillie Gifford.</li><li>Temasek, Arkema, and Johnson &amp; Johnson Innovation also participated.</li><li>The round brought Carbon's total funding up to $680M with a $2.4B valuation, according to VentureBeat sources.</li><li>The funds will go towards R&amp;D, expansion in Europe and Asia, and an Advanced Development Facility.</li><li>Public peers on the move: 3D Systems (<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corporation'>DDD</a> <font color='green'>+2.4%</font>), Stratasys (<a href='https://seekingalpha.com/symbol/SSYS' title='Stratasys Ltd.'>SSYS</a> <font color='green'>+0.7%</font>), ExOne (<a href='https://seekingalpha.com/symbol/XONE' title='The ExOne Company'>XONE</a> <font color='green'>+1.1%</font>), and Voxeljet (<a href='https://seekingalpha.com/symbol/VJET' title='voxeljet AG'>VJET</a> <font color='green'>+0.8%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3473602\" data-linked=\"3D printers rise on $260M startup funding\" data-tweet=\"$DDD $SSYS $XONE - 3D printers rise on $260M startup funding https://seekingalpha.com/news/3473602-3d-printers-rise-on-260m-startup-funding?source=tweet\" data-url=\"https://seekingalpha.com/news/3473602-3d-printers-rise-on-260m-startup-funding\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473600\" data-ts=\"1561472182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PYX\" target=\"_blank\">PYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473600-pyxus-soars-after-imperial-capital-points-to-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pyxus soars after Imperial Capital points to upside</a></h4><ul> <li>Pyxus International (<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a> <font color='green'>+33.5%</font>) rallies after being singled out by Imperial Capital as a company that could outperform in the Canada cannabis market.</li> <li>Imperial Capital thinks Pyxus could attractive interest from a large company similar to the Constellation Brands investment in Canopy Growth.</li><li>Shares of PYX are initiated at Outperform by IC.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473600\" data-linked=\"Pyxus soars after Imperial Capital points to upside\" data-tweet=\"$PYX - Pyxus soars after Imperial Capital points to upside https://seekingalpha.com/news/3473600-pyxus-soars-after-imperial-capital-points-to-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3473600-pyxus-soars-after-imperial-capital-points-to-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473597\" data-ts=\"1561472041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473597-match-bull-sees-continuing-tinder-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Match bull sees continuing Tinder gains</a></h4><ul><li>Jefferies affirms its Buy rating and \"top pick\" designation on Match Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) with the Street-high target of $80.</li><li>Analyst Brent Thill praises the \"consistency and staying power\" of Tinder with no \"red flags\" in the Q2 data. HE remains confident in MTCH's \"ability to work longer-term.\"</li><li>With shares up nearly double from a November low, Thill understands valuation concerns but points out MTCH trades at a discount to its peer group.</li><li>Match shares are <font color=\"red\">down 2.8%</font> to $69.50.</li><li>MTCH has an Outperform <a href=\"https://seekingalpha.com/symbol/MTCH/ratings/sell-side-ratings?s=mtch\" target=\"_blank\">average Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473597\" data-linked=\"Match bull sees continuing Tinder gains\" data-tweet=\"$MTCH - Match bull sees continuing Tinder gains https://seekingalpha.com/news/3473597-match-bull-sees-continuing-tinder-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3473597-match-bull-sees-continuing-tinder-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473595\" data-ts=\"1561471763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HALO\" target=\"_blank\">HALO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473595-halozyme-inks-enhanze-deal-nih-unit-in-hiv\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halozyme inks Enhanze deal with NIH unit in HIV</a></h4><ul><li>Halozyme (<a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a> <font color='green'>+1.4%</font>) enters into an <a href=\"https://seekingalpha.com/pr/17554334-halozyme-announces-crada-national-institute-allergy-infectious-diseases-use-enhanze-drug\" target=\"_blank\">agreement </a>with the NIH's National Institute of Allergy and Infectious Diseases' Vaccine Research Center aimed at leveraging HALO's ENHANZE drug delivery technology to develop subcutaneous formulations of broadly neutralizing antibodies against HIV.</li><li>First up are early-stage studies to assess the safety, tolerability, dose and pharmacokinetics of the two candidates.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473595\" data-linked=\"Halozyme inks Enhanze deal with NIH unit in HIV\" data-tweet=\"$HALO - Halozyme inks Enhanze deal with NIH unit in HIV https://seekingalpha.com/news/3473595-halozyme-inks-enhanze-deal-nih-unit-in-hiv?source=tweet\" data-url=\"https://seekingalpha.com/news/3473595-halozyme-inks-enhanze-deal-nih-unit-in-hiv\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473592\" data-ts=\"1561471603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OR\" target=\"_blank\">OR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473592-osisko-gold-ups-secondary-offering-1m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Osisko Gold ups secondary offering by 1M shares</a></h4><ul><li>Osisko Gold Royalties (<a href='https://seekingalpha.com/symbol/OR' title='Osisko Gold Royalties Ltd'>OR</a> <font color=\"red\">-4.5%</font>) says it will increase its previously announced <a href=\"https://seekingalpha.com/pr/17554865-osisko-announces-increase-previously-announced-secondary-offering\" target=\"_blank\">bought-deal offering</a> to 7.85M common shares from 6.85M shares.</li><li>The seller, Orion Resource Partners, would raise total gross proceeds of more than $110M in the deal; OR will not receive any proceeds of the secondary offering.</li><li>OR also will purchase for cancellation more than 12.3M of its common shares from Orion.</li><li>Upon closing of the secondary offering and share repurchase and  prior to the exercise of an over-allotment option, Orion's ownership of  OR's issued and outstanding common shares will be reduced to 7% from  19.5%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473592\" data-linked=\"Osisko Gold ups secondary offering by 1M shares\" data-tweet=\"$OR - Osisko Gold ups secondary offering by 1M shares https://seekingalpha.com/news/3473592-osisko-gold-ups-secondary-offering-1m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3473592-osisko-gold-ups-secondary-offering-1m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473575\" data-ts=\"1561470194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTES\" target=\"_blank\">GTES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473575-gates-industrialplus-10-on-goldman-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gates Industrial +10% on Goldman upgrade</a></h4><ul><li>Gates Industrial (NYSE:<a href='https://seekingalpha.com/symbol/GTES' title='Gates Industrial Corporation plc'>GTES</a>) <font color=\"green\">soars 10%</font> in early trade after Goldman Sachs analyst Jerry Revich <a href=\"https://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Upgrades+Gates+Industrial+Corp.+%28GTES%29+to+Buy/15641441.html\" target=\"_blank\">upgraded</a> the stock to Buy from Neutral, but maintained his $15 price target.</li><li>He says shares are now trading at a 12% discount to his Machinery &amp; Diversified Industrials coverage, and with consensus expecting it to bottom over the next 1-2 quarters, the risk/reward for shares is now favorable.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473575\" data-linked=\"Gates Industrial +10% on Goldman upgrade\" data-tweet=\"$GTES - Gates Industrial +10% on Goldman upgrade https://seekingalpha.com/news/3473575-gates-industrialplus-10-on-goldman-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3473575-gates-industrialplus-10-on-goldman-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473573\" data-ts=\"1561469753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABBV\" target=\"_blank\">ABBV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473573-abbvie-in-talks-allergan-for-6minus-7-weeks-cnbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AbbVie in talks with Allergan for 6-7 weeks - CNBC</a></h4><ul><li>According to CNBC's David Faber, AbbVie (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color=\"red\">-12.9%</font>) was negotiating its deal with Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color=\"green\">+28.2%</font>) for six or seven weeks before today's announcement. CEO Rick Gonzalez initiated talks.</li><li>Allergan will re-domicile as a U.S. company as a result.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473573\" data-linked=\"AbbVie in talks with Allergan for 6-7 weeks - CNBC\" data-tweet=\"$ABBV $AGN - AbbVie in talks with Allergan for 6-7 weeks - CNBC https://seekingalpha.com/news/3473573-abbvie-in-talks-allergan-for-6minus-7-weeks-cnbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3473573-abbvie-in-talks-allergan-for-6minus-7-weeks-cnbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473567\" data-ts=\"1561469340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DERM\" target=\"_blank\">DERM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473567-dermira-up-9-premarket-on-abbvie-allergan-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dermira up 9% premarket on Abbvie/Allergan deal</a></h4><ul><li>Dermira (NASDAQ:<a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a>) is up <font color=\"green\">9%</font> premarket on light volume as buying ripples out from AbbVie's bid for Allergan.</li><li>Its top drug is Obrexza (glycopyrronium) for primary axillary hyperhidrosis (excessive underarm sweating), approved in the U.S. a year ago.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473567\" data-linked=\"Dermira up 9% premarket on Abbvie/Allergan deal\" data-tweet=\"$DERM - Dermira up 9% premarket on Abbvie/Allergan deal https://seekingalpha.com/news/3473567-dermira-up-9-premarket-on-abbvie-allergan-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3473567-dermira-up-9-premarket-on-abbvie-allergan-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473561\" data-ts=\"1561468906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TIF\" target=\"_blank\">TIF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473561-tiffanyminus-1-after-loop-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tiffany -1% after Loop downgrade</a></h4><ul> <li>Loop Capital Markets lowers Tiffany (NYSE:<a href='https://seekingalpha.com/symbol/TIF' title='Tiffany & Co.'>TIF</a>) to a Hold rating from Buy on concerns over tourism trends.</li> <li>\"We believe weak tourist traffic continues to impact global demand levels, and we are concerned that SSS growth may prove more difficult to achieve as the company laps its paper flowers launch. We think macroeconomic uncertainties have built since our last positive deep dive in mid-April.\"</li> <li>The Loop analyst team slices its price target on the luxury retailer to $95 from $110. The consensus <a href=\"https://seekingalpha.com/symbol/TIF/ratings/sell-side-ratings\" target=\"_blank\">sell-side PT</a> is still all the way up at $107.75.</li> <li>Shares of Tiffany are <font color=\"red\">down 0.92%</font> premarket to $91.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473561\" data-linked=\"Tiffany -1% after Loop downgrade\" data-tweet=\"$TIF - Tiffany -1% after Loop downgrade https://seekingalpha.com/news/3473561-tiffanyminus-1-after-loop-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3473561-tiffanyminus-1-after-loop-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473560\" data-ts=\"1561468876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473560-agn-kndi-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AGN, KNDI among premarket gainers</a></h4><ul><li>Allergan plc (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) <font color=\"green\">+31%</font> as AbbVie is in the final stages of a<a href=\"https://seekingalpha.com/news/3473483-abbvie-poised-take-allergan-60b\" target=\"_blank\"> $188/share bid</a>.</li><li>Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware, Inc.'>PHUN</a>) <font color=\"green\">+15%</font> on the successful <a href=\"https://seekingalpha.com/pr/17554515-phunware-launches-blockchain-enabled-data-exchange-mobile-loyalty-ecosystem\" target=\"_blank\">launch</a> of its Blockchain-Enabled Data Exchange and Mobile Loyalty Ecosystem for current customers.</li><li>Pyxus (NYSE:<a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a>) <font color=\"green\">+18%</font>.</li><li>Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+15%</font>.</li><li>Dermira (NASDAQ:<a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a>) <font color=\"green\">+13%</font> as Almirall <a href=\"https://seekingalpha.com/pr/17553917-almirall-exercises-option-dermira-license-rights-lebrikizumab-europe-atopic-dermatitis\" target=\"_blank\">exercises</a> its option to license rights to Lebrikizumab in Europe for atopic dermatitis.</li><li>Marathon Patent (NASDAQ:<a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>) <font color=\"green\">+6%</font>.</li><li>Evolus (NASDAQ:<a href='https://seekingalpha.com/symbol/EOLS' title='Evolus, Inc.'>EOLS</a>) <font color=\"green\">+7%</font> on AbbVie's Allergan <a href=\"https://seekingalpha.com/news/3473509-evolus-8-percent-premarket-abbvies-allergan-bid\" target=\"_blank\">bid</a>.</li><li>Kandi Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a>) <font color=\"green\">+7%</font> as <a href=\"https://seekingalpha.com/news/3473542-china-ev-market-looks-recharge\" target=\"_blank\">China EV market</a> looks to recharge.</li><li>VBI Vaccines (NASDAQ:<a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines Inc.'>VBIV</a>) <font color=\"green\">+5%</font>.</li><li>Grubhub (NYSE:<a href='https://seekingalpha.com/symbol/GRUB' title='Grubhub Inc.'>GRUB</a>) <font color=\"green\">+5%</font> as Citi <a href=\"https://seekingalpha.com/news/3473519-grub-plus-3_9-percent-citi-turns-bullish-growth\" target=\"_blank\">turns bullish</a> on growth.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473560\" data-linked=\"AGN, KNDI among premarket gainers\" data-tweet=\"$AGN $PHUN $PYX - AGN, KNDI among premarket gainers https://seekingalpha.com/news/3473560-agn-kndi-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473560-agn-kndi-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473559\" data-ts=\"1561468774\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCDA\" target=\"_blank\">TCDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473559-tricida-up-2-premarket-on-publication-of-veverimer-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tricida up 2% premarket on publication of veverimer data</a></h4><ul><li>Tricida (NASDAQ:<a href='https://seekingalpha.com/symbol/TCDA' title='Tricida, Inc.'>TCDA</a>) <a href=\"https://seekingalpha.com/pr/17554450-tricida-announces-publication-positive-long-term-phase-3-clinical-trial-results-veverimer\" target=\"_blank\">announces </a>the publication of <a href=\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2819%2931388-1/fulltext\" target=\"_blank\">results </a>from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03317444?lead=tricida&amp;phase=2&amp;rank=3\" target=\"_blank\">TRCA-301E</a>, evaluating lead candidate veverimer (TRC101) for the treatment of metabolic acidosis in patients with chronic kidney disease &#40;CKD&#41;. The data are in the latest online edition of <em>The Lancet</em>.</li><li>The study met the <a href=\"https://seekingalpha.com/news/3446543-tricidas-lead-candidate-successful-ckd-extension-study-shares-38-percent\" target=\"_blank\">primary efficacy endpoint</a> of a statistically significant proportion of treated patients achieving at least a 4 mmol/L increase in serum bicarbonate compared to placebo. Specifically, 63% of patients receiving veverimer hit the threshold versus 38% for control (p=0.0015). Higher bicarbonate concentrations were observed at all timepoints.</li><li>The safety profile was favorable. Serious adverse events occurred in 2% of the treatment group compared to 5% in the control group. The rate of renal system adverse events also favored veverimer, 8% vs. 15%.</li><li><a href=\"https://www.tricida.com/trc101/\" target=\"_blank\">Veverimer </a>is a non-absorbed polymer that binds to hydrochloric acid in the GI tract and is removed through feces excretion, thereby lowering the amount of acid in the body.</li><li>The company expects to file a U.S. marketing application in H2.</li><li>Shares are up <font color=\"green\">2%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473559\" data-linked=\"Tricida up 2% premarket on publication of veverimer data\" data-tweet=\"$TCDA - Tricida up 2% premarket on publication of veverimer data https://seekingalpha.com/news/3473559-tricida-up-2-premarket-on-publication-of-veverimer-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3473559-tricida-up-2-premarket-on-publication-of-veverimer-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473557\" data-ts=\"1561468672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473557-abbv-and-acer-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ABBV and ACER among premarket losers</a></h4><ul><li>Acer Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACER' title='Acer Therapeutics Inc.'>ACER</a>) <font color=\"red\">-79%</font> after <a href=\"https://seekingalpha.com/news/3473543-fda-rejects-acers-edsivo-application-rare-connective-tissue-disorder\" target=\"_blank\">FDA rejects</a> Edsivo application for rare connective tissue disorder.</li><li>Cemtrex (NASDAQ:<a href='https://seekingalpha.com/symbol/CETX' title='Cemtrex, Inc.'>CETX</a>) <font color=\"red\">-30%</font>.</li><li>Aldeyra Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>) <font color=\"red\">-22%</font> after reproxalap <a href=\"https://seekingalpha.com/news/3473494-aldeyras-reproxalap-flunks-late-stage-anterior-uveitis-study\" target=\"_blank\">flunks</a> late-stage anterior uveitis study.</li><li>Immunic (NASDAQ:<a href='https://seekingalpha.com/symbol/IMUX' title='Immunic, Inc.'>IMUX</a>) <font color=\"red\">-17%</font>.</li><li>VivoPower International (NASDAQ:<a href='https://seekingalpha.com/symbol/VVPR' title='VivoPower International PLC'>VVPR</a>) <font color=\"red\">-13%</font>.</li><li>Cesca Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc.'>KOOL</a>) <font color=\"red\">-10%</font> <a href=\"https://seekingalpha.com/news/3473552-axp-ii-deal-india-fails-lift-cesca-shares-7-percent-premarket\" target=\"_blank\">despite</a> of AXP II deal in India.</li><li>AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3473483-abbvie-poised-take-allergan-60b\" target=\"_blank\">Allergan</a> acquisition.</li><li>Palatin Technologies (NYSEMKT:<a href='https://seekingalpha.com/symbol/PTN' title='Palatin Technologies, Inc.'>PTN</a>) <font color=\"red\">-10%</font>.</li><li>Brighthouse Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/BHF' title='Brighthouse Financial, Inc.'>BHF</a>) <font color=\"red\">-8%</font> on analyst <a href=\"https://seekingalpha.com/news/3473535-brighthouse-minus-6_9-percent-two-downgrades-cite-interest-rate-risk\" target=\"_blank\">downgrade</a>.</li><li>Akorn (NASDAQ:<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a>) <font color=\"red\">-7%</font> on receiving FDA <a href=\"https://seekingalpha.com/news/3473505-akorn-shares-halted-pending-news\" target=\"_blank\">warning letter</a> related to deficiencies noted during an on-site inspection.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473557\" data-linked=\"ABBV and ACER among premarket losers\" data-tweet=\"$ACER $CETX $ALDX - ABBV and ACER among premarket losers https://seekingalpha.com/news/3473557-abbv-and-acer-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3473557-abbv-and-acer-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473554\" data-ts=\"1561468004\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/K\" target=\"_blank\">K</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473554-consumer-edge-research-warns-on-headwinds-for-kellogg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer Edge Research warns on headwinds for Kellogg</a></h4><ul> <li>Kellogg (NYSE:<a href='https://seekingalpha.com/symbol/K' title='Kellogg Company'>K</a>) is on watch after Consumer Edge Research drops the food manufacturer to an Underweight rating from Equal Weight.</li> <li>\"While we think the company is taking the right steps for the long-term, they are coming at a higher than expected cost &amp; risk. In our view, recently increased spot grain prices (+~20%) foretell an H2 cost headwind to offset recent energy &amp; freight tailwinds,\" warns CER.</li> <li>The firm assigns a price target of $49 to Kellogg.</li><li>The consensus <a href=\"https://seekingalpha.com/symbol/K/ratings/sell-side-ratings\" target=\"_blank\">sell-side rating</a> on Kellogg is Hold.</li> <li>Shares of Kellogg are <font color=\"red\">down 0.52%</font> premarket to $55.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473554\" data-linked=\"Consumer Edge Research warns on headwinds for Kellogg\" data-tweet=\"$K - Consumer Edge Research warns on headwinds for Kellogg https://seekingalpha.com/news/3473554-consumer-edge-research-warns-on-headwinds-for-kellogg?source=tweet\" data-url=\"https://seekingalpha.com/news/3473554-consumer-edge-research-warns-on-headwinds-for-kellogg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473552\" data-ts=\"1561467721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOOL\" target=\"_blank\">KOOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473552-axp-ii-deal-in-india-fails-to-lift-cesca-shares-down-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AXP II deal in India fails to lift Cesca, shares down 7% premarket</a></h4><ul><li>Thinly traded nano cap Cesca Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc.'>KOOL</a>) slips <font color=\"red\">7% </font>premarket on average volume despite the <a href=\"https://seekingalpha.com/pr/17554452-cordlife-use-thermogenesis-axp-ii-system-rapid-processing-cord-blood-units-india\" target=\"_blank\">news </a>that subsidiary ThermoGenesis has inked an agreement with Cordlife Group Limited to provide its next-generation AXP II System for processing cord blood units at Cordlife's India processing facility.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473552\" data-linked=\"AXP II deal in India fails to lift Cesca, shares down 7% premarket\" data-tweet=\"$KOOL $THMO - AXP II deal in India fails to lift Cesca, shares down 7% premarket https://seekingalpha.com/news/3473552-axp-ii-deal-in-india-fails-to-lift-cesca-shares-down-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3473552-axp-ii-deal-in-india-fails-to-lift-cesca-shares-down-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473550\" data-ts=\"1561467448\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BNED\" target=\"_blank\">BNED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473550-barnes-noble-education-reports-sales-drop-amid-digital-pivot\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble Education reports sales drop amid digital pivot</a></h4><ul> <li>Barnes &amp; Noble Education (NYSE:<a href='https://seekingalpha.com/symbol/BNED' title='Barnes & Noble Education, Inc.'>BNED</a>) reports retail sales fell 4.5% to $15.2M in <a href=\"https://seekingalpha.com/pr/17554476-barnes-and-noble-education-reports-fourth-quarter-fiscal-year-2019-financial-results\" target=\"_blank\">FQ4</a>.</li> <li>Comparable sales were up 0.9% as the Spring Rush period extended into the quarter due to later school openings and the continued pattern of students buying course materials later in the semester.</li><li>Consolidated non-GAAP adjusted EBITDA fell 12% to $19.7M.</li> <li>Looking ahead, Barnes &amp; Noble Education anticipates FY20 consolidated adjusted EBITDA of between $90M to $100M and free cash flow of $25M to $40M.</li> <li>\"We are beginning to establish positive momentum as we continue to pivot our platforms and offerings to digital delivery,\" says Barnes &amp; Noble Education CEO Michael Huseby.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3473536-barnes-and-noble-education-misses-revenue\" target=\"_blank\">Barnes &amp; Noble Education misses on revenue</a> (June 25)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473550\" data-linked=\"Barnes &amp; Noble Education reports sales drop amid digital pivot\" data-tweet=\"$BNED - Barnes &amp; Noble Education reports sales drop amid digital pivot https://seekingalpha.com/news/3473550-barnes-noble-education-reports-sales-drop-amid-digital-pivot?source=tweet\" data-url=\"https://seekingalpha.com/news/3473550-barnes-noble-education-reports-sales-drop-amid-digital-pivot\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473545\" data-ts=\"1561467099\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRTX\" target=\"_blank\">MRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473545-mirati-prices-stock-offering-97\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mirati prices stock offering at $97</a></h4><ul><li>Mirati Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a>) <a href=\"https://seekingalpha.com/pr/17554462-mirati-therapeutics-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 2.1M common shares at $97 per share. Underwriters over-allotment is an additional 315K shares. Closing date is June 27.</li><li>Yesterday's close was $100.75.</li><li>Shares are up <font color=\"green\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473545\" data-linked=\"Mirati prices stock offering at $97\" data-tweet=\"$MRTX - Mirati prices stock offering at $97 https://seekingalpha.com/news/3473545-mirati-prices-stock-offering-97?source=tweet\" data-url=\"https://seekingalpha.com/news/3473545-mirati-prices-stock-offering-97\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473543\" data-ts=\"1561466669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACER\" target=\"_blank\">ACER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473543-fda-rejects-acers-edsivo-application-for-rare-connective-tissue-disorder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA rejects Acer&#39;s Edsivo application for rare connective tissue disorder</a></h4><ul><li>Thinly traded micro cap Acer Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACER' title='Acer Therapeutics Inc.'>ACER</a>) is poised for a significant down move this morning on the <a href=\"https://seekingalpha.com/pr/17554495-acer-therapeutics-receives-complete-response-letter-u-s-fda-use-edsivo-celiprolol-veds\" target=\"_blank\">news </a>that it received a Complete Response Letter &#40;CRL&#41; from the FDA regarding its marketing application for EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS), an inherited collagen disorder characterized by thin, translucent easily bruised skin.</li><li>The CRL cites the need for a new clinical trial to assess celiprolol's effect on reducing the risk of clinical events in vEDS patients.</li><li>Shares, currently halted, will resume trading at 9:00 am ET.</li><li><strong>Update</strong>: Shares are down <font color=\"red\">76%</font> premarket on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473543\" data-linked=\"FDA rejects Acer&#39;s Edsivo application for rare connective tissue disorder\" data-tweet=\"$ACER - FDA rejects Acer&#39;s Edsivo application for rare connective tissue disorder https://seekingalpha.com/news/3473543-fda-rejects-acers-edsivo-application-for-rare-connective-tissue-disorder?source=tweet\" data-url=\"https://seekingalpha.com/news/3473543-fda-rejects-acers-edsivo-application-for-rare-connective-tissue-disorder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473539\" data-ts=\"1561465964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOVA\" target=\"_blank\">DOVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473539-dovas-doptelet-okd-in-europe-for-low-blood-platelets-shares-up-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dova&#39;s Doptelet OK&#39;d in Europe for low blood platelets; shares up 4% premarket</a></h4><ul><li>Thinly traded micro cap Dova Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DOVA' title='Dova Pharmaceuticals, Inc.'>DOVA</a>) is up <font color=\"green\">4%</font> premarket on light volume on the heels of European Commission <a href=\"https://seekingalpha.com/pr/17554376-dova-pharmaceuticals-announces-european-union-marketing-authorization-doptelet-avatrombopag\" target=\"_blank\">approval </a>of DOPTELET (avatrombopag) for severe thrombocytopenia (low blood platelets) in adults with chronic liver disease who are scheduled to undergo an invasive procedure.</li><li>The FDA approved it for the indication in May 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473539\" data-linked=\"Dova&#39;s Doptelet OK&#39;d in Europe for low blood platelets; shares up 4% premarket\" data-tweet=\"$DOVA - Dova&#39;s Doptelet OK&#39;d in Europe for low blood platelets; shares up 4% premarket https://seekingalpha.com/news/3473539-dovas-doptelet-okd-in-europe-for-low-blood-platelets-shares-up-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3473539-dovas-doptelet-okd-in-europe-for-low-blood-platelets-shares-up-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473535\" data-ts=\"1561465904\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHF\" target=\"_blank\">BHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473535-brighthouseminus-6_9-two-downgrades-cite-interest-rate-risk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brighthouse -6.9% as two downgrades cite interest rate risk</a></h4><ul><li>Brighthouse Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/BHF' title='Brighthouse Financial, Inc.'>BHF</a>) <font color=\"red\">sinks 6.9% </font>in premarket trading after at least two analysts downgrade the stock as declining interest rates are likely to dent earnings.</li><li>Credit Suisse cuts BHF to underperform from neutral and slashes price target to $22 from $35.</li></ul><ol><li>Sees lower interest rates reducing distributable earnings by $1.0B over the next three years and a \"substantial hit\" to GAAP book value from FASB accounting changes.</li></ol><ul><li>Goldman Sachs cuts to sell from neutral and price target to $32 from $39.</li></ul><ol><li>Sees \"little to no distributable earnings from the variable annuity business.</li></ol><ul><li>Quant rating <a href=\"https://seekingalpha.com/symbol/BHF/ratings/quant-ratings\" target=\"_blank\">Very Bullish</a>, Sell-side average rating <a href=\"https://seekingalpha.com/symbol/BHF/ratings/sell-side-ratings\" target=\"_blank\">Hold </a>(1 Buy, 12 Hold, 2 Underperform, 1 Sell), average price target $42.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473535\" data-linked=\"Brighthouse -6.9% as two downgrades cite interest rate risk\" data-tweet=\"$BHF - Brighthouse -6.9% as two downgrades cite interest rate risk https://seekingalpha.com/news/3473535-brighthouseminus-6_9-two-downgrades-cite-interest-rate-risk?source=tweet\" data-url=\"https://seekingalpha.com/news/3473535-brighthouseminus-6_9-two-downgrades-cite-interest-rate-risk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473531\" data-ts=\"1561465531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MVRBF\" target=\"_blank\">MVRBF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473531-stifel-likes-viking-therapeutics-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel likes Viking Therapeutics in premarket analyst action</a></h4><ul><li>Medivir AB (<a href='https://seekingalpha.com/symbol/MVRBF' title='Medivir AB &#40;publ&#41;'>OTC:MVRBF</a>) initiated with Buy rating at H.C. Wainwright.</li><li>Cassava Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SAVA' title='Cassava Sciences, Inc.'>SAVA</a>) initiated with Buy rating and $3 (124% upside) price target at Maxim Group. Shares up <font color=\"green\">8% </font>premarket.</li><li>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) initiated with Buy rating and $14 (107% upside) price target at Stifel. Shares up <font color=\"green\">3% </font>premarket.</li><li>Intercept Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals, Inc.'>ICPT</a>) initiated with Hold rating and $89 (12% upside) price target at Stifel.</li><li>Madrigal Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a>) initiated with Hold rating and $126 (25% upside) price target at Stifel.</li><li>NGM Biopharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/NGM' title='NGM Biopharmaceuticals, Inc.'>NGM</a>) initiated with Buy rating and $26 (88% upside) price target at Stifel.</li><li>Viking Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics, Inc.'>VKTX</a>) initiated with Buy rating and $14 (76% upside) price target at Stifel. Shares up <font color=\"green\">3% </font>premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473531\" data-linked=\"Stifel likes Viking Therapeutics in premarket analyst action\" data-tweet=\"$MVRBF $SAVA $CBAY - Stifel likes Viking Therapeutics in premarket analyst action https://seekingalpha.com/news/3473531-stifel-likes-viking-therapeutics-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3473531-stifel-likes-viking-therapeutics-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473525\" data-ts=\"1561464735\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVTL\" target=\"_blank\">PVTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473525-pivotalminus-4-bofaml-becomes-first-bear\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pivotal -4% as BofAML becomes first bear</a></h4><ul><li>Bank of America Merrill Lynch downgrades Pivotal (NYSE:<a href='https://seekingalpha.com/symbol/PVTL' title='Pivotal Software, Inc.'>PVTL</a>) from Neutral to Underperform with the target dropping from $16 to $12.</li><li>Analyst Nikolay Beliov thinks the recent pullback will continue over the next 12 months. He thinks management is \"making the right moves to address market and execution challenges,\" but that will take time.</li><li>Beliov says the stock needs a bigger discount on the expected subscription revenue deceleration.</li><li>PVTL shares are <font color=\"red\">down 4.2%</font> pre-market to $10.87.</li><li>Pivotal has a Very Bearish <a href=\"https://seekingalpha.com/symbol/PVTL/ratings/quant-ratings\" target=\"_blank\">Quant rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473525\" data-linked=\"Pivotal -4% as BofAML becomes first bear\" data-tweet=\"$PVTL - Pivotal -4% as BofAML becomes first bear https://seekingalpha.com/news/3473525-pivotalminus-4-bofaml-becomes-first-bear?source=tweet\" data-url=\"https://seekingalpha.com/news/3473525-pivotalminus-4-bofaml-becomes-first-bear\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473523\" data-ts=\"1561464599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473523-morgan-stanley-sees-downside-on-blue-apron\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley sees more downside on Blue Apron</a></h4><ul> <li>Morgan Stanley slashes its price target on Blue Apron (NYSE:<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>) to a Street-low $6 (split adjusted) on concerns that fundamentals for the online meal kit provider are crumbling and competition will continue to pressure sales.</li><li>MS is more negative than the sell-side as a whole, which is still sitting on a consensus Hold rating. Meanwhile, SA Authors are Very Bearish on Blue Apron and the <a href=\"https://seekingalpha.com/symbol/APRN/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li> <li>Shares of Blue Apron are <font color=\"green\">up 2.69%</font> premarket to $6.88.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473523\" data-linked=\"Morgan Stanley sees more downside on Blue Apron\" data-tweet=\"$APRN - Morgan Stanley sees more downside on Blue Apron https://seekingalpha.com/news/3473523-morgan-stanley-sees-downside-on-blue-apron?source=tweet\" data-url=\"https://seekingalpha.com/news/3473523-morgan-stanley-sees-downside-on-blue-apron\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473522\" data-ts=\"1561464496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473522-trovagene-files-for-150m-mixed-shelf-shares-down-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trovagene files for $150M mixed shelf; shares down 5% premarket</a></h4><ul><li>Nano cap Trovagene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) slips <font color=\"red\">5%</font> premarket on light volume in reaction to its <a href=\"https://www.sec.gov/Archives/edgar/data/1213037/000110465919037267/a19-12040_1s3.htm\" target=\"_blank\">filing </a>for a $150M mixed shelf offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473522\" data-linked=\"Trovagene files for $150M mixed shelf; shares down 5% premarket\" data-tweet=\"$TROV - Trovagene files for $150M mixed shelf; shares down 5% premarket https://seekingalpha.com/news/3473522-trovagene-files-for-150m-mixed-shelf-shares-down-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3473522-trovagene-files-for-150m-mixed-shelf-shares-down-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473519\" data-ts=\"1561464132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473519-grubplus-3_9-citi-turns-bullish-on-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GRUB +3.9% as Citi turns bullish on growth</a></h4><ul><li>Citi upgrades GrubHub (NYSE:<a href='https://seekingalpha.com/symbol/GRUB' title='Grubhub Inc.'>GRUB</a>) from Neutral to Buy and raises the PT from $75 to $91.</li><li>Analyst Mark May cites GRUB's ability to grow gross food sales around 20% despite the rising food delivery competition, which should help the company hit management's Q4 EBITDA/order guidance.</li><li>May cites restaurant chain data when saying GRUB could be in early tests with McDonald's and Starbucks.</li><li>More action: Cowen (Outperform, $103) calls GrubHub one of its best small- and mid-cap ideas for 2019 with the stock \"cheap historically.\"</li><li>GRUB shares are <font color=\"green\">up 3.9%</font> pre-market to $75.</li><li>GRUB has an Outperform <a href=\"https://seekingalpha.com/symbol/GRUB/ratings/sell-side-ratings\" target=\"_blank\">average Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473519\" data-linked=\"GRUB +3.9% as Citi turns bullish on growth\" data-tweet=\"$GRUB - GRUB +3.9% as Citi turns bullish on growth https://seekingalpha.com/news/3473519-grubplus-3_9-citi-turns-bullish-on-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3473519-grubplus-3_9-citi-turns-bullish-on-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473514\" data-ts=\"1561463811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMX\" target=\"_blank\">BPMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473514-biopharmx-up-60-premarket-on-positive-bpxminus-04-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioPharmX up 60% premarket on positive BPX-04 data</a></h4><ul><li>Nano cao BioPharmX (NYSEMKT:<a href='https://seekingalpha.com/symbol/BPMX' title='BioPharmX Corporation'>BPMX</a>) is up <font color=\"green\">60%</font> premarket on robust volume in response to <a href=\"https://seekingalpha.com/pr/17554178-biopharmx-announces-positive-topline-results-phase-2b-trial-bpxminus-04-papulopustular\" target=\"_blank\">positive results</a> from a Phase 2b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03667222?lead=biopharmx&amp;phase=1&amp;rank=1\" target=\"_blank\">PRISM</a>, evaluating topical minocycline gel BPX-04 in patients with moderate-to-severe <a href=\"https://www.aad.org/public/diseases/acne-and-rosacea/rosacea\" target=\"_blank\">papulopustular rosacea</a>, a skin disorder akin to acne in appearance.</li><li>The study met the primary and secondary endpoints, demonstrating a statistically significant improvement in the number of facial inflammatory lesions and a two-grade improvement to clear or almost clear skin from baseline to week 12.</li><li>A Phase 3 study is next up.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473514\" data-linked=\"BioPharmX up 60% premarket on positive BPX-04 data\" data-tweet=\"$BPMX - BioPharmX up 60% premarket on positive BPX-04 data https://seekingalpha.com/news/3473514-biopharmx-up-60-premarket-on-positive-bpxminus-04-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3473514-biopharmx-up-60-premarket-on-positive-bpxminus-04-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473509\" data-ts=\"1561462898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EOLS\" target=\"_blank\">EOLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473509-evolus-up-8-premarket-on-abbvies-allergan-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evolus up 8% premarket on AbbVie&#39;s Allergan bid</a></h4><ul><li>Evolus (NASDAQ:<a href='https://seekingalpha.com/symbol/EOLS' title='Evolus, Inc.'>EOLS</a>) is up <font color=\"green\">8%</font> premarket, albeit on light volume, on the heels of AbbVie's $63B bid for BOTOX maker Allergan.</li><li>In May, the FDA approved Jeuveau, its product for the treatment of frown lines.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473509\" data-linked=\"Evolus up 8% premarket on AbbVie&#39;s Allergan bid\" data-tweet=\"$EOLS - Evolus up 8% premarket on AbbVie&#39;s Allergan bid https://seekingalpha.com/news/3473509-evolus-up-8-premarket-on-abbvies-allergan-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3473509-evolus-up-8-premarket-on-abbvies-allergan-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473506\" data-ts=\"1561462585\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473506-bausch-healths-duobrii-lotion-now-available-in-u-s-shares-up-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bausch Health&#39;s DUOBRII lotion now available in U.S.; shares up 4% premarket</a></h4><ul> <li>Bausch Health Companies (NYSE:<a href='https://seekingalpha.com/symbol/BHC' title='Bausch Health Companies Inc.'>BHC</a>) has <a href=\"https://seekingalpha.com/pr/17554105-bausch-health-announces-u-s-launch-duobrii-halobetasol-propionate-tazarotene-lotion-0_01\" target=\"_blank\">launched</a> DUOBRII (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045% in U.S. for patients with plaque psoriasis.</li><li>The FDA approved DUOBRII is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation.</li>  <li>DUOBRII Lotion is priced at $825 for a a 100-gram tube.</li><li>Shares are up <font color=\"green\">4%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3473506\" data-linked=\"Bausch Health&#39;s DUOBRII lotion now available in U.S.; shares up 4% premarket\" data-tweet=\"$BHC - Bausch Health&#39;s DUOBRII lotion now available in U.S.; shares up 4% premarket https://seekingalpha.com/news/3473506-bausch-healths-duobrii-lotion-now-available-in-u-s-shares-up-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3473506-bausch-healths-duobrii-lotion-now-available-in-u-s-shares-up-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473505\" data-ts=\"1561462411\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKRX\" target=\"_blank\">AKRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473505-akorn-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akorn shares halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Akorn (NASDAQ:<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a>) pending the release of news.</li><li><strong>Update</strong>: The company has received a <a href=\"https://seekingalpha.com/pr/17554201-akorn-receives-fda-warning-letter\" target=\"_blank\">Warning Letter</a> from the FDA related to deficiencies noted during an on-site inspection at its Somerset, NJ manufacturing facility in July/August 2018. Management says it will respond to the letter within the required 15 working days.</li><li><strong>Update</strong>: Shares are down <font color=\"red\">10%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473505\" data-linked=\"Akorn shares halted pending news\" data-tweet=\"$AKRX - Akorn shares halted pending news https://seekingalpha.com/news/3473505-akorn-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3473505-akorn-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473503\" data-ts=\"1561462251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIMHF\" target=\"_blank\">WIMHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473503-william-hillplus-4-caesars-potential-highlighted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">William Hill +4% as Caesars potential highlighted</a></h4><ul> <li>William Hill ([WIMHY]], <a href='https://seekingalpha.com/symbol/WIMHF' title='William Hill plc'>OTCPK:WIMHF</a>) makes an announcement following the Eldorado Resorts-Caesars deal.</li> <li>The company notes it has an agreement to exclusively operate sports books at all properties owned or managed by Eldorado in the U.S. and to operate mobile sports betting in states where Eldorado obtains a license, including the rights to Caesars properties after the deal is completed.</li> <li><a href=\"http://www.williamhillplc.com/newsmedia/newsroom/corporate-news/2019/william-hill-plc-statement/\" target=\"_blank\">William Hill press release</a></li> <li>Shares of William Hill are <font color=\"green\">up 3.65%</font> in London trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473503\" data-linked=\"William Hill +4% as Caesars potential highlighted\" data-tweet=\"$WIMHF - William Hill +4% as Caesars potential highlighted https://seekingalpha.com/news/3473503-william-hillplus-4-caesars-potential-highlighted?source=tweet\" data-url=\"https://seekingalpha.com/news/3473503-william-hillplus-4-caesars-potential-highlighted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473500\" data-ts=\"1561462045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEN\" target=\"_blank\">LEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473500-lennarplus-5_2-q2-results-beats-sees-fatter-margins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lennar +5.2% as Q2 results beats; sees fatter margins</a></h4><ul><li>Lennar (NYSE:<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a>) <font color=\"green\">jumps 5.2%</font> in premarket trading after its <a href=\"https://seekingalpha.com/pr/17554012-lennar-reports-second-quarter-eps-1_30\" target=\"_blank\">fiscal Q2 results</a> beat estimates as the housing market improved.</li><li>Sees margin improvement in the next two quarters, driven by lumber savings and direct cost synergies from its CalAtlantic acquisition.</li><li>A market pause in H2 of 2018 \"set the stage for more moderate home price increases and lower interest rates which stimulated both affordability and demand, leading homebuyers back to the market, said Executive Charman Stuart Miller.</li><li>Gross margin for the quarter ended May 31, 2019, though was hurt by an 80-basis point increase in incentives offered to homebuyers during the market pause; gross margin on home sales of 20.1% compares with 16.8% in the year-ago quarter.</li><li>Q2 EPS of $1.30 beat the average analyst estimate of $1.14 and increased from 94 cents a year ago.</li><li>Q2 total revenue of $5.56B  exceeded the $5.13B consensus estimate and  rose from $5.46B a year earlier.</li><li>Q2 deliveries rose 5% Y/Y to 12,729 homes.</li><li>Q2 new orders of 14,518 homes rose 1% Y/Y; new orders dollar value of $5.8B fell 4%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3473479-lennar-eps-beats-0_16-beats-revenue\" target=\"_blank\">Lennar EPS beats by $0.16, beats on revenue</a> (June 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3473500\" data-linked=\"Lennar +5.2% as Q2 results beats; sees fatter margins\" data-tweet=\"$LEN - Lennar +5.2% as Q2 results beats; sees fatter margins https://seekingalpha.com/news/3473500-lennarplus-5_2-q2-results-beats-sees-fatter-margins?source=tweet\" data-url=\"https://seekingalpha.com/news/3473500-lennarplus-5_2-q2-results-beats-sees-fatter-margins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473494\" data-ts=\"1561461053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDX\" target=\"_blank\">ALDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473494-aldeyras-reproxalap-flunks-late-stage-anterior-uveitis-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aldeyra&#39;s reproxalap flunks late-stage anterior uveitis study</a></h4><ul><li>Aldeyra Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>) is poised for a significant down move this morning after <a href=\"https://seekingalpha.com/pr/17554084-aldeyra-therapeutics-announces-results-solace-trial-noninfectious-anterior-uveitis\" target=\"_blank\">announcing </a>that a Phase 3 clinical trial, SOLACE, evaluating reproxalap in patients with noninfectious anterior uveitis failed to achieve the primary or secondary endpoints.</li><li>Reproxalap did not sufficiently separate from vehicle (placebo) due to the high rates of disease resolution in the vehicle arm.</li><li>The company will terminate development for this indication but will continue its programs in dry eye disease, allergic conjunctivitis and proliferative vitreoretinopathy.</li><li>Shares will resume trading at 7:30 am ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473494\" data-linked=\"Aldeyra&#39;s reproxalap flunks late-stage anterior uveitis study\" data-tweet=\"$ALDX - Aldeyra&#39;s reproxalap flunks late-stage anterior uveitis study https://seekingalpha.com/news/3473494-aldeyras-reproxalap-flunks-late-stage-anterior-uveitis-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3473494-aldeyras-reproxalap-flunks-late-stage-anterior-uveitis-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473491\" data-ts=\"1561460772\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHOP\" target=\"_blank\">SHOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473491-shopifyminus-3-after-wedbush-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shopify -3% after Wedbush cut</a></h4><ul> <li>Wedbush lowers Shopify (NYSE:<a href='https://seekingalpha.com/symbol/SHOP' title='Shopify Inc.'>SHOP</a>) to a Neutral rating from Outperform on a valuation call to follow a day after a similar <a href=\"https://seekingalpha.com/news/3473193-shopify-drops-roth-moves-cautious\" target=\"_blank\">cut</a> by Roth Capital Partners.</li> <li>\"While we continue to like Shopify's positioning, vision, and competitive moat as it builds a strong retail operating system for merchants,\" advises Wedbush analyst Ygal Arounian.</li> <li>Even with the two downgrades, the <a href=\"https://seekingalpha.com/symbol/SHOP/ratings/sell-side-ratings\" target=\"_blank\">sell-side consensus rating</a> is still Outperform.</li> <li>Shares of Shopify are <font color=\"red\">down 2.73%</font> premarket to $303.30 after shedding 4.59% yesterday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3473491\" data-linked=\"Shopify -3% after Wedbush cut\" data-tweet=\"$SHOP - Shopify -3% after Wedbush cut https://seekingalpha.com/news/3473491-shopifyminus-3-after-wedbush-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3473491-shopifyminus-3-after-wedbush-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>152&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3473488\" data-ts=\"1561460435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDX\" target=\"_blank\">ALDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3473488-aldeyra-shares-halted-ahead-of-reproxalap-data-readout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aldeyra shares halted ahead of reproxalap data readout</a></h4><ul><li>Nasdaq has suspended trading in Aldeyra Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>) ahead of its conference call this morning at 8:00 am ET to discuss topline data from a late-stage study of reproxalap in noninfectious anterior uveitis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3473488\" data-linked=\"Aldeyra shares halted ahead of reproxalap data readout\" data-tweet=\"$ALDX - Aldeyra shares halted ahead of reproxalap data readout https://seekingalpha.com/news/3473488-aldeyra-shares-halted-ahead-of-reproxalap-data-readout?source=tweet\" data-url=\"https://seekingalpha.com/news/3473488-aldeyra-shares-halted-ahead-of-reproxalap-data-readout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}